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ABSTRACT 
Gene therapy holds promise for the treatment of many medical ailments.  Understanding 
the genetic basis of disease, coupled with advances in modern medicine, fuels the search 
for disease treatment at the genetic level.  However, gene therapy is far from the standard 
of care after thirty years of research and development.  Progress is limited by the need for 
a gene delivery platform that is both safe and highly efficient.  Viral vectors have evolved 
to deliver genetic material efficiently to target cells, but suffer from a host of potential 
safety and immunogenic concerns.  Conversely, comparatively less efficient non-viral 
delivery methods result from poor understanding of rational design required for a 
successful synthetic, ground-up approach to gene delivery.  Barriers to gene delivery 
must thus first be identified and overcome before rational design can take place. 
 
The plasma membrane represents one important barrier in the gene delivery process.  The 
method by which vectors are internalized and subsequently trafficked plays a key role in 
determining their intracellular fate.  Recent research has shown, for example, that vector 
interaction with different regions of the plasma membrane can result in endocytosis 
directed to endolysosomes, the Golgi apparatus, or the endoplasmic reticulum.  Each of 
these destinations affects whether the ultimate goal of vector delivery to the nucleus for 
expression is achieved.  Moreover, the milieu of intracellular sorting vesicles points to 
the complexity of the trafficking process – one in which endocytic pathways are not 
clearly defined, and may involve pathway interplay that has been hitherto unexplored.  
Our primary aim was therefore to understand the interplay of common endocytic 
mechanisms in non-viral gene delivery.   
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Vector-targeting to cell surface receptors is one method of enhancing gene delivery to 
specific cells.  However, receptor-specific internalization has a direct effect on the 
endocytic trafficking process that must be taken into account in vector design.  While 
many ligands are used successfully to target vectors to different tissues that overexpress 
their receptor, their precise mechanisms of endocytosis and processing en route to the 
nuclear region is undefined.  We thus also seek to elucidate the relationships between 
receptor-specific targeting and endocytosis as they relate to synthetic gene delivery. 
 
The research presented in this thesis describes the issue of different methods of vector 
internalization and how they affect subsequent gene delivery.  Chapter 2 discusses the 
roles of clathrin and caveolar processing in polyethylenimine and polyamidoamine 
polymer gene delivery.  Our results show that these processes are not necessarily 
independent of each other.  Intracellular sorting exists by which synthetic vectors 
internalized by one mechanism may still be dependent on another for successful gene 
delivery.  We further developed this study approach in Chapter 3 by examining the 
impact of targeting polyplexes to clathrin and caveolae, using transferrin and folic acid 
ligands, respectively.  Once again, our findings suggest that pathways are not delineated 
simply by their method of endocytosis because of the existence of complex sorting 
mechanisms that take effect following vector uptake into the cell.  In the final chapter, we 
explored the trafficking mechanisms of the integrin receptor, one that is highly implicated 
in cancer, metastasis, and angiogenesis, but of which the precise method of trafficking as 
it relates to gene delivery is currently unexplored.   
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This logical approach to understanding gene delivery started with identifying significant 
pathways involved in the delivery process, characterizing these pathways by studying the 
processing of ligands known to traverse them, and finally exploring the arginine-glycine-
aspartic acid (RGD) ligand targeted to the integrin receptor in the context of our previous 
discoveries.  Lysosomal avoidance and trafficking via the caveolar pathway were 
recurring motifs for successful gene delivery in our experiments.  Incorporating these 
principles to design of polymeric gene delivery vehicles will likely enhance gene delivery 
efficiency and the development of the synthetic vector field for clinical application.
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CHAPTER 1 
 
Introduction 
 
Gene Therapy 
The basis for gene therapy lies in recognizing that all diseases comprise a genetic 
component.  Technological advances in modern medicine have made possible the 
identification of specific genetic defects implicated in a large number of diseases.  This, 
coupled with development of therapeutic gene delivery systems, has resulted in gene 
therapy becoming a potentially viable treatment option for many medical ailments.   
 
Disease can be differentiated into three broad categories based on the relationship 
between its genetic cause and age of onset: chromosomal defects, which usually occur 
prenatally and are manifested early in life; single-gene Mendelian defects, such as 
hemophilia, disorders of metabolism, and cystic fibrosis; and multifactorial diseases that 
typically develop later in life, including heart disease, hypertension, and cancer (Fig. 1.1).  
From its inception to the present day, gene therapy research has largely focused on 
treatments for Mendelian and multifactorial diseases. 
 
The concept of gene therapy is over half a century old, but it was only after the structure 
of DNA had been elucidated in 1953 that it began to be explored as a potential treatment 
for disease [1-8].  Since then, the definition of gene therapy has not changed significantly.  
The American Society of Gene and Cell Therapy currently defines gene therapy as a “set 
of strategies that modify the expression of an individual’s genes or that correct abnormal 
genes”.  The vast majority of genetic ailments result from null mutations in which the 
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downstream protein loses its original function.  For example, a well-studied target for 
gene therapy is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.  
Over a thousand potential mutations in the CFTR gene have been documented, but the 
most common mutations leading to disease result in non-functional, rapidly degraded 
CFTR protein [9].  Local, limited insertion of functional CFTR protein has been shown to 
restore normal physiology in test subjects [10-13].  Similarly, null tumor protein 53 is 
implicated in over fifty percent of all cancers [14].  As with cystic fibrosis, diseases 
resulting from mutations in the TP53 gene are caused by non-functional protein [15, 16].  
Damage to p53 results in uncontrolled cell division and cancer, while restoration of 
endogenous p53 function holds much promise in treatment. 
 
 
 
The methodologies and foci of gene therapy applications have developed dramatically 
over the past forty years.  Continuing advances in technology and medicine are making a 
significant difference in how disease is identified, diagnosed, and ultimately treated.  For 
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Figure 1.1. Distribution of diseases by age of onset. 
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example, the Human Genome Project greatly contributed to the identification of common 
genetic defects and their associated diseases.  Today, a host of high-throughput, 
massively parallel sequencing technologies under development promises affordable, 
personalized medical gene profiling [17-25].  These sequencing technologies have 
potential to replace even relatively recent advances in this field, such as DNA 
microarrays.  The application of gene therapy to the treatment of inherited disease and 
single-gene Mendelian disorders was evident during early years of gene research [3].  But 
technological advances described above have highlighted the very prevalent role of genes 
in multifactorial diseases – diseases that typically occur later in life, and often as a result 
of a multiplicity of factors working in tandem (Figure 1.1).  Today, nearly three quarters 
of all gene therapy clinical trials aim to treat cancer and heart disease (Figure 1.2) [26].  
 
Figure 1.2. Distribution of gene therapy clinical trials by disease. 
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While the premise and opportunity for gene therapy development are well-established, 
the track record for development of a commercial gene therapy treatment for any disease 
has been disappointing.  Gene therapy research has focused on three classes of delivery 
platform: physical methods, non-viral vectors, and viral vectors.  Viruses have evolved to 
deliver cargo DNA to cells and demonstrate high gene delivery efficiency.  A significant 
portion of the gene therapy research community is focused on tailoring viral vectors for 
treatment application.  However, compared with non-viral and physical methods of 
delivery, viruses carry a higher risk of immunogenic response.  The death of a patient as a 
direct result of the recombinant adenovirus used in a 1999 University of Pennsylvania 
clinical trial has since resulted in more cautious approaches to the gene therapy field [27-
29].  Synthetic, non-viral methods are minimally immunogenic but, at the state-of-the-art, 
are still at least an order of magnitude less efficient than the best performing viral 
platforms.  Viral vectors generally transfect a greater proportion of target cells, and effect 
higher levels of, and longer lasting, transgene expression.  Yet, limited progress in 
treatment development is due largely to potential toxicity and immunogenicity of current 
gene delivery vectors.  To-date, the U.S. Food and Drug Administration (FDA) has not 
approved any gene therapy product for sale.   The major obstacles to gene therapy today 
are the same as they were 30 years ago: development of safe and efficient delivery 
platforms suitable for clinical application [30, 31]. 
 
Physical Methods of Delivery 
Physical approaches to gene delivery entail delivery of naked DNA to the cell or nucleus 
without a delivery vehicle.  Unlike viral or synthetic delivery platforms utilizing a 
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delivery vehicle, physical methods demonstrate minimal toxicity or immunogenicity.  
However, they are limited largely by practical in vivo applicability.  Naked DNA 
delivery is untargeted and unprotected.  As a result, significantly higher quantities of 
therapeutic DNA are used in physical delivery approaches to compensate for the high 
attrition rate of cargo DNA to delivery inefficiencies, such as nuclease degradation and 
poor trafficking to non-target locations within the cell.  Methods in physical approaches 
have thus focused on developing targeted delivery processes to overcome this 
shortcoming.  This overview of physical methods will briefly discuss the advantages and 
shortcomings of three well-established, technologies commonly used in laboratory gene 
therapy: electroporation, hydroporation, and ultrasound microbubble delivery. 
 
Electroporation 
Electroporation is a well-developed laboratory technique used to permeate the plasma 
membrane and facilitate cellular entry of a target extracellular particle.  Its application to 
the gene therapy field has been explored for almost three decades [32].  The presence of 
an electric field, typically 200 V/cm in vivo, is necessary to permeate cell membranes.  
Compared with naked DNA injection, electroporation increases transfection efficiency by 
two to three orders of magnitude [33, 34].  DNA internalization mechanisms during 
electroporation are not well-characterized.  Several studies have contradicted the 
‘hydrophilic pore formation’ hypothesis by which plasmid DNA was believed to cross 
the plasma membrane after application of an electric field [35-37], proposing instead 
some form of non-specific interaction between plasmid DNA and the plasma membrane 
leading to endocytosis.  Regardless, in addition to poor specificity, electroporation has 
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been shown to potentially induce tissue damage [38].  Enhancing specificity for in vivo 
applications often necessitates invasive surgical procedures to bring electrodes into close 
proximity with the target area.  Electroporation has nonetheless been successfully used in 
cancer treatment applications, including tumor cell permeabilization prior to delivery a 
cytotoxic drug [39].   
 
Continued research in the past decade has emphasized development of electroporation 
protocols that minimize toxicity by modulating exposure duration and field intensity.  
Specifically, the use of syringe electrodes capable of generating focused, low intensity 
fields were shown to generate localized in vivo transfection levels comparable to plate 
electrodes that had a larger, but more stable, field output [40].  Similarly, exposing target 
tissue to alternating high and low fields reduced field ‘dose’ while maintaining gene 
delivery comparable to that of higher field strength for the same period of time [41, 42].  
Electroporation gene therapy has seen continued interest and progress despite its 
limitations of tissue toxicity and potentially invasive field application protocols.  Indeed, 
a wide range of tissues have since been studied in vivo in addition to skin treatment, 
including vasculature, cardiac muscle, lung, liver, spinal cord, brain, cornea, and retina 
[43-48].  
 
High Pressure Delivery Methods 
In the absence of a targeted delivery vehicle, entry of naked DNA into cells can be 
facilitated by directing DNA to target tissues under high pressure.  Early approaches 
using this method involved particle bombardment [49], where plasmid DNA-coated 
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nanoparticles were discharged into cells to effect transfection.  While relatively effective, 
non-invasive in vivo treatment applications of the ‘gene gun’ system were limited.  
Treatment area was also limited by the surface area covered by the particle stream.  
Clinically, effectiveness of this method has not expanded beyond dermal and subdermal 
drug or gene delivery applications [50]. 
 
Hydrodynamic gene delivery uses a rapidly delivered, high volume injection of DNA in 
solution to effect transfection in target tissues.  Tissue hydroporation is achieved by 
employing a hypertonic solution on cells at elevated hydrostatic pressure.  This method is 
widely used for in vivo gene therapy studies in rodents via tail vein injection [51-56], 
where the injection volume varies from 8-10% of body weight.  Successful gene delivery 
to parenchyma cells occurs after disruption of the endothelial barrier during this 
hydrodynamic loading.  Osmotic and hydrostatic pressures allow naked DNA to then 
infiltrate structures in close proximity to the vasculature.  Liver, kidney, and muscle 
tissue adjacent to the location of injection have been shown to be effective gene delivery 
targets in hydrodynamic gene delivery [57, 58].  The liver is an especially promising 
target due to its central location in hepatic portal circulation.   
 
Endothelial structure of the capillary, as well as tissue and organ architecture surrounding 
the vasculature, are the principle determinants of gene delivery efficiency via 
hydrodynamic loading [59, 60].  Structures close to fenestrated capillaries are more likely 
to be effectively transfected due to the loose connections between adjacent endothelial 
cells and the absence of a basal lamina.  The liver is highly susceptible to hydroporation 
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due to the porous nature inherent to the organ’s sinusoids, resulting in enhanced 
permeability following application of hydrodynamic pressure.  Conversely, continuous 
capillaries and their associated tissue are poor targets for uniform gene delivery.   
 
Although hydrodynamic gene delivery has shown increased effectiveness over other 
physical methods, it remains a highly invasive technique with many side effects.  Most 
notably, these include decreased heart rate and increased blood pressure as a result of the 
sudden rise in total blood volume during injection [52, 61, 62].  Proponents of the method 
point to rapid recovery in rodents, with only transient increases of liver enzymes in blood 
following the procedure, and blood composition returning to normal with 72 hours [63, 
64].  Structural insults are repaired even more quickly.  The expanded liver returns to 
normal size within 30 minutes [65], and hydroporated sinusoids and hepatocytes are 
resealed within minutes of treatment [66, 67].  
 
Development of this procedure for human clinical application has focused on reducing 
the injection volume while maintaining the necessary hydrodynamic pressure for gene 
delivery [61].  One solution is to perform direct injection of a comparatively small 
volume of solution (~1% bodyweight) directly into target organ vasculature [68], rather 
than into large blood vessels.  In humans, this would reduce the potential stress of a 
rapidly changing vascular volume on the cardiac muscle.  The injection insult would thus 
be locally limited.  Many other considerations, such as precise control over the rate of 
injection and invasiveness, must still be addressed before this method can be considered 
for disease treatment. 
 9 
 
Ultrasound Gene Delivery 
Ultrasound-based gene delivery hybridizes biological carrier mechanisms normally seen 
in viral and synthetic viral approaches to gene delivery with physical methods of 
deploying the carrier and its cargo DNA.  Electroporation and hydroporation discussed in 
the previous sections mediate efficient, if relatively invasive, gene delivery.  Ultrasound 
methods are minimally invasive in comparison.  Clinical use of ultrasound for imaging, 
ultrasonic shock waves for kidney stone destruction, and even high-intensity ultrasound 
for tumor ablation, are non invasive and result in minimal patient discomfort. 
 
Gene delivery via ultrasound typically involves encapsulation of cargo DNA within a 
gas-filled lipid or polymer ‘microbubble’.  These microbubbles are typically 1-8 µm in 
diameter, with an outer shell several hundred nanometers thick [69].  The outer shell 
layer may be targeted to specific tissues types using receptor-specific ligands.  
Microbubble particles are injected systemically or locally, with release of cargo DNA at 
the target site mediated by a focused ultrasound pulse that ruptures the microbubbles [70, 
71].  Shell material and thickness affect resistance to ultrasound rupture, as well as 
rapidity with which the fragments are cleared by the reticuloendothelial system following 
application of the ultrasound pulse [72]. 
 
Ultrasound based gene delivery thus enables protection of cargo DNA from degradation 
during circulation and site-specific gene transfer.  Relatively low dose ultrasound (1 min 
at 1 MHz, 2.5 W/cm2) is sufficient to effect gene delivery comparable to electroporation 
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in target tissues [73].  Increasing doses did not significantly raise ultrasound-mediated 
transfection.  Ultrasound has been used to effect gene delivery in a host of tissues, 
including cardiac [74-76], skeletal [77-79], and ciliary muscle [80].  Applications for 
cancer treatment have also been tested in solid tumors [72, 81], melanoma [82], and 
carcinoma [83, 84].  Ligand targeting to specific vascular tissues has been particularly 
effective.  In vitro and in vivo successes have been reported using ultrasound to target 
gene delivery to rejected cardiac tissue [85], activated endothelium [86], vasculature 
associated with lymphatic tissue [87], platelets [88], and angiogenic endothelium [89-92].  
Targeting to angiogenic vasculature was achieved by conjugating the integrin ligands to 
the microbubble shell to facilitate both imaging and drug delivery to the diseased sites.  
Given the widespread use of ultrasound as a clinically acceptable diagnostic and a 
treatment modality, it is not difficult to envision maturation of its gene therapy 
applications into mainstream treatment options. 
 
Of the three physical methods discussed in this introduction, ultrasound-based gene 
delivery bears the greatest similarity to carrier-based transfection methods seen in clinical 
trials with viral vectors, both in terms of minimal invasiveness and potential for targeted 
specificity.  Arguably, ultrasound gene therapy has also shown the most promise of 
becoming a clinical applicable physical method of gene therapy.  Electroporation and 
hydroporation demonstrate high transfection, proof of principle, and ease of use as 
research tools.  Their clinical applicability for disease treatment, however, is yet to be 
validated on account of unacceptable tissue insult and invasiveness.  The subsequent 
 11 
section explores viral gene delivery as the method of choice in clinical trials for these 
reasons.   
 
Viral Gene Delivery Vectors 
Classification of Common Viral Vectors 
Viruses have evolved over millennia to effectively deliver cargo DNA to target cells.  As 
such, they are highly efficient and robust transfection agents.  Retroviruses, adenoviruses, 
and adeno-associated viruses (AAV) are the most commonly used viral vectors in current 
clinical trials and will be covered in this section (Table 1.1) [93, 94].   
Table 1.1 Comparison of commonly used viral vectors 
Virus Gene Material Packaging 
capability (kB) 
Chromosome 
integration 
Key properties 
     
Adenovirus dsDNA 30 No Short term expression 
AAV ssDNA 5 No Small payload 
Retrovirus RNA 8 Yes Infects quiescent and 
dividing cells 
Herpes simplex 
virus-1 
dsDNA 40 No Targets neurons 
 
The adenovirus and retrovirus differ in both their payload capacity and duration of gene 
expression.  Retrovirus infection results in the integration of cargo DNA into the host 
genome, leading to long term expression.  However, this carries with it the risk of non-
specific insertional mutagenesis in the host genome.  Adenoviruses mediate gene delivery 
to the host nucleus without integration [95].  This results in transient expression that is 
usually terminated following host cell division as the viral genome is not passed on to 
daughter cells.  Similar to adenoviruses, AAVs typically do not integrate cargo DNA into 
the host cell genome, but can infect quiescent cells.  Long term expression can be 
established by preferential integration into one specific locus in human chromosome 19 
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[96].  AAVs are non-pathogenic and have not been identified as etiologic for human 
disease, in large part due to their inherent requirement of a helper virus to facilitate AAV 
production [97].  As a result of replication deficiency and widespread pre-existing 
immunity to the AAV, AAV gene delivery presents a low risk of immunogenic response 
in humans [97, 98].   
 
Adenovirus 
Targeting to specific cell types is a requirement for many gene therapy applications.  The 
adenovirus requires cell surface receptors for efficient gene delivery.  Cell entry 
preferentially occurs via the coxsackie adenovirus receptor (CAR), and integrin αVβ3 and 
αVβ5 proteins in the plasma membrane [99].  Overexpression of both CAR and integrin 
receptors in various cancers has made them prominent receptor-based targets for tissue 
specific gene and drug delivery [99-101].  Recent adenoviral gene therapy studies have 
targeted head and neck [102], prostate [103], colon [104], pancreas [105], cervical [106], 
and solid tumor [107] cancers, as well as vascular endothelium and angiogenic tissue 
[108].  Endocytosis of this virus via glycosaminoglycans has also been observed [109, 
110].  Adenovirus escape from endosomes following endocytosis, and its subsequent 
trafficking to the nucleus along microtubules, has served as a model trafficking pathway 
for synthetic, non-viral vector design [111]. 
 
Adenoviruses possess several advantages over retroviruses and AAVs in the context of 
clinical gene therapy applications: 1) subtype adenovirus C is non-oncogenic, 2) deletion 
of native E1 regions in the viral genome render it replication deficient, 3) large cargo 
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capacity, and 4) inherent targeting for multiple gene therapy applications [99, 111, 112].  
Notably, these are also motivators of non-viral vector development.   
 
Early gene therapy research emphasized the inherent adenovirus tropism for integrin 
receptor expressing tissues in development of a cystic fibrosis gene therapy.  Many 
members of the integrin receptor family, including αVβ3, are expressed in airway tissue.  
Targeted delivery and sustained expression of the cystic fibrosis transmembrane regulator 
(CFTR) protein in affected airway tissue would restore salt balance and minimize lung 
failure due to infection and inflammation [113-116].  Unfortunately, poor transfection in 
the epithelium resulted from either topical application [117-119] or nebulized aerosol 
[120-122] delivery to the airway.  Airway delivery proved to be limited by both immune 
response and poor access of the vector directly to affected tissues, while intravenous 
delivery generated yet greater immunogenicity [10, 116, 123, 124].  The transient nature 
of adenoviral gene delivery is another potential drawback for cystic fibrosis applications, 
even after the obstacles described above have been overcome. 
 
Adeno-Associated Virus 
Like glycosaminoglycan-mediated adenoviral cell entry, AAVs are endocytosed via 
similar proteoglycans [125].   They are non-immunogenic and have the potential to effect 
long term expression; however, the frequency of permanent integration is low [126].  A 
significant drawback of the AAV vehicle is its limited payload and low infectivity.  Low 
infectivity may be due to dependence on helper viruses for reproduction [97].  The 
advantages and disadvantages of this vehicle were evident during early clinical 
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application of AAVs for cystic fibrosis.  Minimal immunogenicity, allowing 
administration of higher titers of virus, was negatively offset by small cargo capacity.  
During several 1990s clinical trials this resulted in inefficient expression due to 
limitations on promoter robustness [127].  Subsequent trials in the early 2000s 
demonstrated better, if only transient, gene expression for cystic fibrosis [121].  AAVs 
experienced renewed interest after it was discovered that the vector could cross the 
blood-brain barrier.  Other delivery applications concurrently under development include 
delivery to brain, skeletal, and heart tissue [128, 129].  More extensive clinical successes 
have been documented in the past four years for the treatment of Leber congenital 
amaurosis with AAV gene therapy.  Patients who underwent photoreceptor degeneration 
as a result of the disease gained significantly restored vision after treatment to increase 
production of the 11-cis-retinal ligand [130-134].  In these patients, sustained production 
of 11-cis-retinal – the chromophore ligand that binds photoreceptors – resulted in 
repopulation of retinal photoreceptors, and eventual eyesight recovery.  Taking into 
account recent successes in achieving higher sustained gene expression with this viral 
vector, the progression of AAV gene delivery research suggests that for the gene delivery 
field as a whole, issues of delivery efficiency and expression are more readily addressed 
than those of immunogenicity. 
 
Retrovirus 
Retroviruses comprise single stranded RNA genomes encased in a protein envelope.  
Various envelope proteins utilize different mechanisms of receptor-mediated endocytosis 
to gain cell entry, and retroviruses thus vary in their ability to transfect dividing and 
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quiescent cells.  They have been used extensively for ex vivo gene therapy strategies 
targeting cells of hematopoietic origin.  In fact, three successful, well-documented 
severe-combined-immunodeficiency (SCID) clinical trials were conducted in 2000 using 
retroviral gene therapy to transfect CD34+ cells ex vivo [135-137].  In each case 
reinfusion of transfected cells into the patient restored normal T-cell levels.  All 30 SCID 
patients treated during that period have restored immune systems, and have been 
essentially cured from SCID for over a decade after treatment [138].   
 
One potential complication of retroviral gene delivery is the risk of random insertional 
mutations that results from integration of the retrovirus genome with that of the host.  
Two SCID patients developed leukemia as a result of vector insertion into the LMO 
proto-oncogene promoter [139].  Action of the retroviral promoter on the proto-oncogene 
is believed to have been the cause of deregulated oncogene transcription.  The dangers of 
such random insertional mutagenesis have driven the development of ‘self-inactivating’ 
retroviral vectors for clinical use [140].  Deletion of a specific sequence in the 3’ long 
terminal repeat of the RNA genome produces a virus devoid of promoters or enhancers, 
minimizing the risk of oncogene activation in the event of inopportune host genome 
insertion.  The idea of controlled site-specific insertion was also proposed to minimize 
the unpredictable effects of retroviral integration [141].  Combining zinc finger nuclease 
technology with integration deficient retroviruses addresses both concerns about random 
insertion and unintended activity of the viral promoter on host genes.  Successful 
implementation of these concepts could lead to a viral gene delivery platform that is 1) 
safely integrated, 2) efficiently expressed, and 3) leads to sustained long-term expression. 
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Non-Viral Gene Delivery Vectors 
The ideal gene delivery vehicle exhibits large DNA capacity, target cell specificity, 
minimal immunogenicity and cytotoxicity, and high gene delivery efficiency.  Synthetic 
vectors possess many of these characteristics and are easily tailored to suit specific 
applications.  Among other advantages, non-viral vectors are easily produced and non- 
immunogenic.  However, despite recent technological advances in synthetic vector design, 
viruses are still more efficient gene delivery vehicles.  One focus of non-viral gene 
delivery research is thus optimizing endocytosis and intracellular trafficking processes to 
facilitate successful delivery and expression of therapeutic DNA during transfection 
[142]. 
 
Lipids and polymers are the two most commonly studied materials in non-viral gene 
delivery.  Both cationic liposomes and polymers maintain strong electrostatic interactions 
with DNA, forming lipo- or polyplexes that are capable of facilitating gene delivery.  
Liposomes have been studied for almost two decades and have become a standard 
laboratory tool for transfection [143-147].  In liposomes, saturation of hydrophic lipid 
tails contributes to lipoplex toxicity and stability [70].  Many lipid formulations have 
been used in gene delivery.  Cationic lipids are typically combined with neutral or helper 
lipids, such as cholesterol and dioleoylphosphatidylethanolamine (DOPE), to stabilize 
liposomes under physiological conditions and aid in membrane fusion [148].  Negatively 
charged liposomes are less frequently used in gene delivery.  Certain anionic 
formulations are capable of fusing with the plasma membrane at low pH, or via energy 
independent means, to deliver their genetic cargo to the cytoplasm [149, 150].  Recent 
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work has provided new evidence suggesting that in polymeric gene delivery vehicles, 
polyplex surface charge determines the mechanism of energy-dependent endocytosis 
[151].  Compared with cationic lipids, cationic polymers are more efficient in condensing 
DNA [152].  Off-the-shelf polymers polyethylenimine (PEI) and polyamidoamine 
(PAMAM) dendrimers have shown great promise as readily functionalized gene delivery 
vehicles for a wide range of targeted tissues [153-162].  Gene delivery with these cationic 
polymers is centered on their hypothesized endosomal escape capabilities (vide infra).  
 
Although polymers and liposomes have been extensively researched for gene therapy, 
current synthetic vehicles are still limited by their low in vivo transfection.  Following 
injection into vasculature, synthetic vectors demonstrate minimal extravasation into 
adjacent target tissues and are frequently cleared by the reticuloendothelial system [163, 
164].   
 
Transient gene expression is another obstacle to widespread use of non-viral vectors.  
Little is known about the fate of plasmid DNA following nuclear delivery or its 
mechanism of inheritance during cell division.  Additionally, the molecular switches 
regulating expression of foreign plasmid in quiescent cells is unknown.  Liposomes have 
only been tested in clinical trials for nasal application in cystic fibrosis.  Success was 
limited in single [165, 166] and multiple applications of the aerosolized vector [167, 168], 
while another double blind placebo trial indicated no significant benefit to CF patients 
[169].  However, researchers did note that patients demonstrated minimal 
immunogenicity to the vector in these trials.  Needless to say, further research is required 
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if synthetic vectors are to achieve the sustained levels of gene expression observed with 
viruses. 
 
It is well-known that polymers and lipoplexes are largely incapable of eliciting an 
immunogenic response.  However, toxicity is frequently the result of the quantities of 
vector needed to achieve measurable therapeutic success.  In cationic polymers with a 
high density of amines, the charge ratios and polymer molecular weight necessary to 
optimally bind and condense cargo DNA has been shown to induce toxicity [170-172].  
In vivo, these vectors have been shown to trigger cytokine-mediated inflammatory 
responses.  One successful attempt to address the issue of toxicity involved co-injection 
of the lipo/polyplex with inflammatory suppressors that inhibit NF-κB production [173].  
Inflammatory responses can also be mounted against DNA in the polyplex.  In a 2000 
study by Alton et al. patients developed transient flu-like symptoms after a nebulized 
vector containing DNA synthesized in bacteria was released into their lungs [174].   
 
Substantial research has been performed to develop minimally toxic polymers.  Synthesis 
of biodegradable polymers is an avenue of research pursued by many groups [175-183].  
These polymers often utilize the reducing cytoplasmic environment to denature disulfide 
bonds in the engineered vector, simultaneously releasing DNA and degrading the 
polymer.  The use of natural and readily biodegradable molecules, such as chitosan and 
albumin, for polyplex encapsulation has also shown promise in minimizing inflammatory 
responses [184-187]. 
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The achievements in addressing issues of immunogenicity, toxicity, and even delivery 
efficiency of synthetic gene delivery in the past two decades are noteworthy considering 
the entirely ground-up approach taken to vector design.  However, lack of efficiency 
compared to their viral vehicle counterparts necessitates a better understanding of the 
barriers involved in the delivery process.  The following section will discuss these 
barriers, as well as modern approaches in synthetic vector engineering taken to overcome 
them.  
 
Gene Delivery Barriers 
Extracellular Barriers 
Delivery of the gene therapy vehicle and its cargo to target tissues at therapeutic doses is 
a prerequisite for successful in vivo treatment.  Three barriers to this process have been 
identified: 1) distribution and extended circulation of the vector, 2) extravasation from 
vasculature to tissues, and 3) discrimination between target and non-target tissue [188].   
 
In liposomes, kinetics of vector circulation can be controlled by modulating lipid 
formulations to enhance stability and reduce clearance rates, although effect on 
transfection efficiency was not significantly affected [188].  Of greater concern are the 
effects of serum on particle aggregation and disruption of the vehicle from its cargo DNA 
[189].  Because polyplexes are held together by electrostatic forces, the presence of 
charged species in serum may result in competitive binding interactions that displace 
DNA.  In fact, this is the proposed mechanism of intracellular polyplex unpackaging in 
several studies [190, 191].  As charged species capable of competing the polymer off its 
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cargo exist both inside and outside the cell, premature release of cargo DNA in the 
extracellular space is of concern as a source of gene delivery inefficiency.   
 
Poly- and lipoplexes with near-neutral zeta-potential values have been shown to 
aggregate with each other when incubated for extended periods of time.  In vivo, even 
charged nanoparticles carry the potential for aggregation effects when exposed to 
opposite charged species in serum and blood cells, resulting in the formation of large 
particles that retard efficient circulation [192].  Such particles will be trapped in the first 
microvascular bed encountered and fail to circulate to tissues more distant from the site 
of injection.  Early research with microspheres suggested that the upper size limit for 
unhindered circulation in vasculature is 4 µm [193].   
 
Synthetic vectors must leave the bloodstream and subsequently reach target cells to effect 
gene delivery.  In the absence of active targeting to the endothelium, extravasation 
typically occurs through fenestrated endothelium in vascular beds (5-10 nm) and in liver 
or spleen sinuses (100 nm) [194, 195].  As most synthetic vectors are at least an order of 
magnitude larger in size than the endothelial gaps described above, intravascular injection 
of vector usually results in vector accumulation in the liver and transfection of those 
parenchymal cells.  However, co-injection of vector with vascular endothelial growth 
factor (VEGF) to temporarily increase microsvasculature permeability was shown to 
enhance the transfection of striated muscle tissue at low AAV doses [196].   
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Delivery to certain types of cancer is surprisingly less complex.  Passive targeting to 
tumors is readily effected because cancer-associated vasculature undergoing angiogenesis 
is significantly more fenestrated, or ‘leaky’, compared with normal blood vessels [197-
199].  Further, macromolecules and other particles that extravasate into the tumor 
because of its hypervasculature are minimally recovered via venous or lymphatic 
drainage.  This has become known as the “enhanced permeability and retention” effect 
[200-202].  Such tumoritropic accumulation of vectors has proven to be a simple means 
of cancer gene delivery [203-205]. 
 
Receptor-Specific Targeting 
Upon reaching the target organ or tissue, vector targeting to specific cell types becomes 
necessary to minimize toxicity or damage to healthy cells.  Conjugation of the vector to 
ligands that bind cell-surface receptors is the most common method inducing artificial 
vector tropism.  Ligand conjugation to polymers and liposomes has been studied 
extensively in vitro as cellular uptake represents the first barrier to successful in vitro 
delivery.  The mechanism by which untargeted lipo/polyplexes is endocytosed is poorly 
understood, although proteoglycans appear to play a role in this process: cells deficient in 
proteoglycan are significantly more difficult to transfect [152].  Cancer tissue targeting 
has been a focus of many receptor-targeted gene delivery platforms as these cells and 
their associated vasculature overexpress a host of receptors.  Among these, folic acid 
[206-215], transferrin [216-229], and integrin [161, 224, 230-236] receptors have proved 
popular targets because of their presence in many tumors, and roles in tumor migration 
and angiogenesis.  Some success using receptor-specific cancer targeting has been 
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reported in vivo.  In particular, Wolschek et al. presented a PEI-based delivery platform 
targeted to the epidermal growth factor (EGF) receptor on xenograft tumors in SCID 
mice [237].  Following intravascular injection, gene expression in the tumor target was 
discovered to be two orders of magnitude higher than in the liver.  Evidence of polyplex 
uptake and degradation was shown in liver cells, with minimal transfection of other non-
specific tissues.  Additional success has been demonstrated using antibody-based gene 
delivery targeted to cell-surface receptors.  These antibody-vector 
immunolipoplex/polyplex conjugates are typically small and highly specific to the 
receptor or cell surface protein targeted, and have been explored for both gene therapy 
and drug delivery applications [238-245]. 
 
Intracellular Barriers 
Vector trafficking from the plasma membrane to the nuclear region, followed by vector 
unpackaging and therapeutic gene transcription, is required for successful gene delivery.  
This route is punctuated by many steps, each of which potentially contributes to 
inefficiency in the gene delivery process.  Viruses have evolved specific mechanisms to 
overcome these barriers.  Some of these functionalities have been successfully 
incorporated into the design of non-viral delivery platforms, but by and large, the in vitro 
inefficiency of synthetic vectors is still attributed to poor intracellular trafficking.    
  
The intracellular fate of the synthetic vector ultimately depends on its mechanism of 
internalization and the destination of the trafficked vesicle.  Vesicles endocytosed from 
clathrin-coated pits in the plasma membrane typically traverse an endolysosomal pathway 
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[188, 246, 247].  It is well established that clathrin vesicles are sorted and recycled in this 
process, where they undergo a drop in pH and exposure to activated proteases and 
nucleases.  Avoidance of this fate is critical to successful gene delivery.  While clathrin is 
present in all mammalian cell lines and plays a significant role in endocytosis, non-
clathrin uptake mechanisms, such as caveolae, have been identified that do not undergo 
acidification and lead to successful gene delivery [248-250].   
 
Caveolae are localized in lipid-raft domains of the cell membrane rich in cholesterol [251, 
252].  Energy dependent endocytosis leads to the formation of caveolar vesicles 
characterized by the presence of caveolin-1, cholesterol, and neutral pH [253].  The high 
localization of the folic acid receptor to cholesterol-rich domains has led to its use as a 
marker for caveolar targeting in gene delivery [254, 255].  Similarly, exploration of 
clathrin-mediated pathways is often mediated via transferrin receptor targeting due to that 
receptor’s association with clathrin coated pits [255-259].   Other ligands that also 
colocalize uniquely with caveolar vesicles are simian virus 40 (SV40) and cholera toxin 
subunit B (CTxB) [260-262].   
 
It is not clear whether caveolar vesicles are designated sorting hubs to other pathways or 
themselves recycling stations because the precise mechanism by which their trafficking 
occurs is poorly defined.  For example, lipid raft markers cholera and shiga toxins 
associate with caveolae but are later colocalized with clathrin-dependent markers [263-
265].  Early research also showed that SV40 and CTX ligands internalized via caveolae 
were ultimately destined for the endoplasmic reticulum and Golgi bodies [266].  It has 
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been proposed that in addition to being capable of intracellular vesicle sorting, selective 
endocytosis of ligands by different cell surface caveosome populations also contributes to 
the selective trafficking observed by caveolae [253].  More recently, Reilly et al. showed 
that PEI polyplexes internalized by caveolae avoid lysosomes by trafficking to the Golgi 
and ER before reaching the nucleus [267] [the reference is missing volume and page 
numbers].  The retrograde ER to Golgi pathways observed in this study are similar to 
those established for pathogens and toxins.  Regardless of the precise trafficking pathway 
taken by the caveolar vesicle, its lack of acidification and exposure to the degrading 
lysosomal environment makes it of particular interest to researchers studying polymer-
mediated gene therapy.   
 
Proton Sponge Effect 
Clathrin-coated vesicles destined for the endolysosome undergo pH decreases, often to 
pH 4.6-5, during trafficking [268, 269].  While liposomes have demonstrated a 
dependence on clathrin-based mechanisms for transfection [270-272], this phenomenon is 
a source of inefficiency for polyplex gene delivery [255].  For nearly two decades, 
variations in endosomal pH have been exploited to enhance gene delivery via the proton-
sponge mechanism [273, 274].  According to this hypothesis, vectors capable of 
buffering pH accumulate in the endosome, resulting in osmotic swelling and eventual 
vesicle rupture.  The subsequent release of polyplexes to the cytosol contributes to the 
enhanced gene delivery activity observed with proton-sponge materials.  PEI and 
PAMAM polymers are two prototypical proton sponge vehicles characterized by a high-
density of primary amines.  These amines facilitate not only pH buffering, but also 
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polymer-DNA binding and condensation via electrostatic interactions.  As proof of 
principle, Gabrielson et al. demonstrated that acetylation of PEI primary amines resulted 
in decreased buffering as well as DNA binding ability [275]. 
 
Endosomotropic buffering agents such as chloroquine are also widely used to enhance the 
gene delivery activity of synthetic vectors lacking inherent buffering capabilities [276, 
277].  Previous work has shown that chloroquine accumulates in endosomes at 
concentrations over two orders of magnitude higher than that in the extracellular 
environment [278].  While the precise contribution of chloroquine to enhanced gene 
delivery is difficult to identify, chloroquine is capable of intercalating DNA to inhibit 
nuclease activity, in addition to its buffering capacity in the endosome [255].  
Interestingly, the use of chloroquine had little effect on the transfection activity of a non-
proton sponge material, poly-L-lysine (PLL) [277].  The possibility that PLL is natively 
trafficked via a pathway that avoids the lysosome, thereby masking potentially beneficial 
effects of chloroquine, has not been precluded.  Chloroquine has thus been used 
extensively as a diagnostic tool to identify the mechanism of uptake and trafficking 
pathways traversed by a synthetic vector.  However, its applicability to in vivo studies is 
toxicity-limited.  Previous work has shown that chloroquine concentrations necessary to 
enhance gene delivery in vitro are already over an order of magnitude higher than levels 
that would result in acute systemic toxicity in rodents [279].   
 
Engineering pH sensitive mechanisms of endosomal escape into synthetic vectors is an 
alternative to chloroquine use [280-284].  Most pH responsive peptides incorporated into 
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non-viral vectors are fusogenic amphiphiles, destabilizing membranes upon undergoing 
structural changes in low pH environments.   Nucleic acid cargo is typically released 
directly from the endosome into the cytoplasm during this process.  The conjugation of 
melittin, an endosomolytic peptide capable of disrupting lipid membranes, to synthetic 
vectors has also demonstrated some success in the area of membrane disruption.  
Enhanced gene delivery activity of PEI-melittin constructs has been attributed to the 
detergent-like properties of the melittin peptide [285-287].   
 
Nuclear Entry 
Translocation of vector or naked DNA from the cytosol into the nucleus represents the 
final physical barrier to gene delivery.  In the case of polyplex or lipoplex delivery 
platforms, unpackaging must occur at some point during the delivery process if the DNA 
is to be eventually transcribed and expressed.  DNA released from polyplexes in the 
perinuclear region has been shown to have the highest likelihood of successfully entering 
the nucleus [288, 289].  Conversely, premature DNA unpackaging in the cytosol is a 
leading cause of its degradation by nucleases.  Research suggests that the half-life of 
unprotected plasmid DNA in the cytosol is between one and two hours [290, 291].  Given 
that less than 0.1% of naked DNA reaches the nucleus in microinjection experiments, 
cytosolic degradation is a leading source of gene delivery inefficiency [292].  However, 
several successful gene delivery methods have involved combining endosomal membrane 
disruption with simultaneous polyplex unpackaging.  For example, incorporation of acid-
sensitive linkers in vector design resulted in polymer destabilization and hydrolysis 
during protonation in the lysosome [293, 294].  This allowed DNA leakage from the 
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polyplex and enhanced gene delivery.  Read et al. have combined similar reducible 
vehicles with histidine and lysine to buffer endosomal pH and mediate a simultaneous 
DNA release and proton-sponge effect [295].  It is possible that the enhanced gene 
delivery observed in these methods of DNA unpackaging, directly from the endosome, is 
the result of nuclear-specific trafficking subsequent to plasmid release. 
 
Plasmid DNA entry into the nucleus typically occurs when the nuclear membrane breaks 
down during mitosis.  However, nuclear entry is limited via pores in the nuclear 
membrane in post-mitotic or quiescent cells.  With the exception of rapidly dividing 
cancer tissue, quiescent cells account for majority of potential in vivo targets, and the 
nuclear membrane thus represents a significant final barrier to in vivo gene delivery.  
Studies showed that nuclear pore entry is heavily regulated by hydrophobic interactions 
between the pore and its cargo [296].  The emphasis on surface hydrophobicity as a 
criterion of pore selectivity has been used to both enhance transmembrane traffic, as well 
as reversibly collapse pore complexes [296].  These interactions can potentially be 
mimicked using non-specific, amphiphilic ligands specially engineered to exploit the 
gating process in these pores.   
 
Conjugation of nuclear localization signals to synthetic vectors is a well-documented 
method of facilitating nuclear entry [297, 298].  Similar to receptor-mediated endocytosis 
at the cell surface as a means of crossing the plasma membrane, incorporation of nuclear-
targeting ligands into vector design is the basis of many gene delivery studies focused on 
crossing the nuclear barrier.  Ligands specific to the nucleus and used in gene delivery 
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applications include nuclear localization signal (NLS) molecules and transcription factors.  
For example, nuclear protein HMGB1, which binds nuclear DNA and regulates 
transcription, has been used to facilitate the transportation of plasmid DNA through the 
nuclear pore complexes during gene delivery [299, 300].  Yi et al. have also extensively 
explored combining TAT and NLS proteins into plasmid vectors in an attempt to 
influence translocation across both the plasma and nuclear membranes [301].  Results 
with TAT-NLS conjugated DNA showed enhanced endocytosis and 200-fold increased 
gene delivery compared to unmodified TAT system, indicating that incorporation of these 
NLS signals increased both cellular uptake and nuclear transport.   
 
Conclusions 
 
Gene therapy undoubtedly holds great promise as a therapeutic agent for a vast number of 
medical ailments.  Its potential in medical applications became apparent soon after the 
discovery of DNA as genetic material more than half a century ago.  Since 1990, more 
than 1500 gene therapy clinical trials have been conducted with both viral and non-viral 
vectors, although to-date the U.S. FDA has not approved any gene therapy drug for sale.  
In most cases, poor therapeutic efficiency or adverse responses to the vector limited 
continued treatment development.  The future success of gene therapy thus lies in 
development of a treatment platform that can efficiently deliver a gene to target cells with 
minimal harm to the patient. 
 
Despite the noted setbacks, the past two decades of ups and downs have achieved several 
important milestones in the gene therapy field.  The first FDA approved antisense 
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antiviral medication – Vitravene – effectively minimized intraocular CMV infection 
[302].  Successful Leber congenital amaurosis treatment based on AAV delivery of 
cDNA carrying the RPE65 gene, with significant clinical benefit and no side effects, is a 
recent documented advancement in clinical treatment [303].  Current clinical trials 
treating various forms of cancer have demonstrated a gene-mediated cytotoxic 
immunotherapy effect, in which patients develop long-standing anti-tumor memory in 
addition to tumor shrinkage [304-308].   
 
Advantages and drawbacks of each method of gene delivery have been discussed in this 
review.  Physical methods, while demonstrating proof of principle delivery efficiency, are 
limited in their practical use for human patients.  Viral vectors are presently the vehicle of 
choice in many gene delivery applications.  Their design has emphasized minimizing 
risks associated with immunological and cancer side effects.  At the same time, non-viral 
approaches have focused on increasing efficiency by recognizing that many extracellular 
and intracellular barriers exist to successful synthetic delivery.  Considering that synthetic 
vectors have demonstrated simplicity of production, use, and safety, continued 
development in efficiency will likely enhance their utility in the clinical setting. 
 
The research documented in this dissertation elucidates the role of endocytosis and 
intracellular trafficking in non-viral gene delivery.  A thorough understanding of these 
barriers to gene delivery is a prerequisite to the rational design on non-viral vectors.  
Only after these barriers have been identified and overcome will non-viral vehicles 
eventually meet the requirements for effective clinical application. 
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CHAPTER 2 
 
Characterization of Polyethylenimine and Polyamidoamine Gene 
Delivery Mechanism 
 
Introduction 
The use of viral and non-viral vectors has been investigated for more than two decades as 
nucleic acid delivery systems for human gene therapy.  However, to-date the U.S. Food 
and Drug Administration has not approved a gene therapy product for sale despite nearly 
1500 clinical trials conducted worldwide [1].  It is widely known that viral gene delivery, 
although efficient, suffers from a plethora of problems at the clinical stage that include 
immunogenicity and oncogenicity, resulting in a brief 2003 FDA ban on retroviral 
vectors in stem cells [2-5].  Polymers, including polyethylenimine (PEI) and 
polyamidoamine (PAMAM) dendrimers among many others, represent a safer and 
inexpensive alternative to viral gene delivery, but suffer from poor transfection efficiency 
and toxicity issues. Branched 25-kDa PEI has been a benchmark for non-viral gene 
delivery since its use was first reported in 1995 [6-10].  However, high toxicity in vivo 
has been a major barrier against clinical development of PEI.   
 
Dendrimers such as polyamidoamine (PAMAM) have also been explored in recent years 
[11-19] as an alternative to PEI-based gene delivery for their potential for modification 
and flexible chemistry.  Like PEI, PAMAM dendrimers complex efficiently with 
negatively charged nucleic acids [17, 20, 21], exhibit molecular weight-dependent 
transfection characteristics [22, 23], and are believed to facilitate endosome escape via 
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the proton-sponge effect [24].  Intracellular mechanisms of PAMAM/DNA polyplexes 
have been investigated [25-28]. 
 
Formation of well-condensed, cationic polyplexes is important for effective polymeric 
gene delivery [29-32].  Size and zeta potential influence polyplex transport to the cell 
surface, as well as subsequent internalization.  Sizes of PEI and PAMAM polyplexes 
formed and measured in deionized water typically range from 80-300 nm [33, 34].  
However, under physiological salt concentration, plasmid DNA polyplexed with cationic 
polymers often form large aggregates in excess of 1000 nm.  Small sizes can be achieved 
at a highly positive nitrogen/phosphate (N/P) charge ratio.  It has been hypothesized that 
aggregation of particles results in enhanced transport to the cell surface, resulting in high 
uptake and gene delivery at higher N/P ratios at the expense of polymer toxicity.  
Conversely, limited transport of small particles to the cell surface results in reduced 
internalization.   
 
Other reports with PEI have shown that free polymer remains in solution at N/P ratios in 
excess of the charge neutral polyplex [35].  Polyplexes retain constant size and absolute 
zeta potential with increasing N/P ratio, although the presence of free polymer increases 
in solution [36].  In polyplexes purported to traffick through low pH endosomes, 
incubation with the buffering agent chloroquine enhances gene expression several-fold.  
These results point to the role of buffering and the proton-sponge effect, rather than 
endocytosis, as the limiting factor in polyplex gene delivery.   
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Internalization and subsequent intracellular trafficking of polymer/DNA complexes 
(polyplexes) have been identified as the key barriers to successful in vitro gene delivery.  
Polyplexes are generally internalized by eukaryotic cells via endocytosis, a term which 
encompasses several distinct pathways.  Two of these pathways – clathrin-mediated 
endocytosis and non-clathrin mediated endocytosis - have been extensively studied in the 
past decade.  It was purported that the high transfection efficiency of PEI was due to its 
ability to act as a “proton sponge” and buffer the acidic endolysosomal environment 
characteristic of the clathrin-dependent pathway [37].  However, that hypothesis has been 
discredited by several groups that have shown successful gene delivery results from 
polyplex avoidance of lysosomes [38-42].   
 
Caveolin-dependent endocytosis is a well researched non-clathrin based pathway that 
plays a role in gene delivery [3, 41, 43-50].  Gabrielson et al. have recently reported that 
caveolar uptake is the effective pathway for gene delivery to HeLa cells by PEI/DNA 
polyplexes [3, 41].  Recent literature presents varying conclusions as to the uptake and 
trafficking of PAMAM-DNA polyplexes.  Some point to trafficking via caveolin-
dependent [16], cholesterol-dependent, [51], and even clathrin-dependent [52, 53] 
pathways. It should be noted that several of these studies use the polymer alone without 
significant cargo. We expect that the mechanism of uptake and trafficking would depend 
on the size and nature of cargo.  Polyplexes can exhibit different sizes and zeta potential 
values, affecting how they aggregate in transfection medium and interact with the cell 
surface.  In this study, we seek to determine the role of both clathrin and caveolar 
pathways in the successful delivery of PAMAM-DNA polyplexes.   
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We investigated the clathrin- or caveolin-dependence of PEI/DNA and PAMAM/DNA 
polyplexes by inhibiting each of these pathways with endocytosis inhibiting drugs.  
Amantadine prevents clathrin-mediated uptake by stabilizing clathrin-coated vesicles and 
preventing clathrin-lattice recycling to the cell surface, thus blocking the budding of the 
clathrin-coated vesicles [54, 55].  Chlorpromazine similarly prevents coated pit formation 
on the plasma membrane by promoting clathrin lattice assembly on endosomal 
membranes [56, 57] and has a probable inhibitory effect on the formation of large 
intracellular vesicles [58]. Methyl--cyclodextrin (MCD) sequesters cholesterol and 
disrupts the lipid-rich domains on the cell surface that form caveolae. Acute plasma 
membrane cholesterol depletion at high MCD concentrations also affects clathrin-
coated pit formation [59-61] as well as exocytosis [62].  Genistein prevents tyrosine 
phosphorylation of caveolin [63] and microtubule polymerization [64], thereby inhibiting 
caveosome formation and subsequent trafficking of the caveolin-dependent pathway. No 
other nonspecific cellular effects have been reported with these drugs unless otherwise 
noted above [58]. 
 
As previous literature has shown, vehicle internalization at the plasma membrane, and its 
subsequent intracellular trafficking toward the nucleus, is highly specific to both vehicle 
and cell line [65].  The HeLa cell line is well-characterized in gene delivery studies, 
exhibits several receptor types typically associated with caveolar and clathrin pathways, 
and possesses active clathrin- and caveolin-dependent, and clathrin- and-caveolin-
independent trafficking pathways.  We have chosen to study 25-kD PEI and G4 PAMAM 
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because they are representative benchmarks of the polymer and dendrimer classes of gene 
delivery vehicles.  Their use in gene and drug delivery is well-characterized [2, 15, 66, 
67].   
 
We report herein the formation of stable PEI and PAMAM polyplexes for gene delivery 
to HeLa cells.  Following polyplex characterization, we determine the effect of endocytic 
inhibitors on cellular uptake of PEI/DNA and PAMAM/DNA polyplexes, and their 
transfection efficiency.  Most significantly, we studied the effect of the endocytosis 
inhibiting drugs on cellular uptake and transfection 1) at different drug concentrations, 2) 
across a range of N/P ratios.  These data illustrate the utilization of the different pathways 
at different degrees of endocytic inhibition.  Confocal microscopy experiments were also 
performed to demonstrate colocalization of polymer-DNA polyplexes with clathrin- or 
caveolin-tagged endocytic vesicles, and provide further evidence of how these vectors 
navigate the intracellular milieu utilizing both clathrin and caveolin pathways.   
 
Results and Discussion 
PEI and PAMAM Polyplex Formation and Characterization 
Electrostatic interactions form the basis for the formation of PEI- and PAMAM-DNA 
polyplexes.  To determine the amount of polymer required to form charge-neutral 
polyplexes, polymer and plasmid were mixed at N/P ratios 1-50 and subjected to gel 
electrophoresis (Figure 2.1).   
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 Neutral and positively-charged polyplexes remain in the loading wells, while negatively-
charged polyplexes and free DNA migrate through the gel.  The polyplex composition at 
which DNA and polyplexes do not enter the gel is defined as the charge-neutral N/P ratio, 
and is a measure of polymer-DNA interaction.  Unmodified PAMAM and 25-kD PEI 
formed charge-neutral polyplexes at relatively low ratios (N/P 2 and 4, respectively).   
 
Ethidium Bromide DNA Condensation 
DNA condensation is another measure of polymer-DNA interaction.  EtBr readily 
intercalates with free and loosely-bound DNA, but is effectively blocked from 
intercalating sites in well-condensed and tightly-bound DNA.  Polyplexes were prepared 
at N/P ratios 0.5-20 for 25-kD PEI and unmodified PAMAM, and subsequently incubated 
with ethidium bromide (Figure 2.2).   
Figure 2.1. DNA gel 
retardation with PAMAM 
(A) and PEI (B) 
polyplexes.  The polymer 
to DNA N/P ratio used to 
form each polyplex is 
given above the 
corresponding lane.   
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
A B
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
1 2 4 6 8 10 15 20 25 30 35 40 50 DN
A
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DNA complexed with unmodified PAMAM or 25-kD PEI achieved maximum 
condensation starting at N/P ratios as low as 2; addition of further polymer did not 
increase EtBr exclusion in PAMAM/DNA polyplexes.  At maximum condensation, PEI 
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Figure 2.2.  Ethidium bromide exclusion in polyplexes formed with unmodified 
PAMAM or PEI, at varying N/P ratios (A) 15 min. (B) 30 min, (C), 120 min and (D) 
240 min after formation of polyplexes. Normalized fluorescence is calculated as (F – 
F0)/(FDNA – F0).  F, fluorescence from solution containing ethidium bromide and the 
polyplexes; F0, fluorescence from solution of ethidium bromide only; and FDNA, 
fluorescence from solution of DNA and ethidium bromide without polymer (N = 4, 
error bars represent standard deviation). 
 
 62 
achieved significantly greater DNA condensation than PAMAM, reducing EtBr dye 
fluorescence by over 90%.  In contrast, maximum PAMAM condensation resulted in only 
60-70% EtBr signal quenching.  Readings taken at 30 min, 2 h, and 4 h showed no 
change in DNA condensation.   
 
pH Titration 
Previously, Gabrielson et al. demonstrated that modulating the buffering capacity of 
proton-sponge polymers resulted in enhanced polymer transfection activity.  This is in 
part due to a trade-off between increased polyplex unpackaging and decreased polymer 
buffering capacity [68].  The hypothesized proton-sponge effect suggests that buffering 
plays a key role in polyplex escape from the endosome by inducing endosomal rupture 
[69-71].  To compare the buffering capacities of PAMAM and PEI, aqueous solutions of 
PEI and PAMAM were titrated with HCl between pH 12-2 (Figure 2.3).   
 
Figure 2.3.  Titration of aqueous 
polymer solutions (1 mg/mL) with 2 
M HCl from pH 12 to 2 at room 
temperature. Solutions were adjusted 
to pH 12 with 1 M NaOH, and 5 µL 
aliquots of 2 M HCl were 
subsequently added and the pH 
measured. 
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Buffering capacity of the two polymers is defined here as the reciprocal slope of the 
titration plots over pH 7.5-4.5 (units of µL of 1M HCl/pH unit, or simply µL).  PEI is a 
strong buffer, exhibiting a slope of 5.78 µL.  PAMAM buffering capacity (4.84 µL) was 
slightly less than PEI.   
 
Polyplex Sizing 
Polyplex sizes determined by dynamic light scattering ranged from 90-150 nm for 
unmodified PAMAM, and from 105-133 nm for PEI polymers (Table 2.1).   
Increasing N/P led to a general decrease in polyplex size, presumably from tighter 
binding.  DLS readings taken after 2 h incubation at room temperature repeatedly showed 
variable increases in size.  Given that EtBr exclusion was constant over this same time 
period, the changes in polyplex sizes are most likely the result of aggregation.  
Aggregation may also have contributed to the relatively large standard deviation of initial 
polyplex size measurements.   
 
We have measured several parameters of PEI and PAMAM polyplex formation to show 
the different DNA binding properties of these two proton-sponge polymers.  Recent work 
Table 2.1.  Polyplex sizing immediately after formation in water.  Polyplexes were 
prepared at N/P ratios 10-50 and subjected to dynamic light scattering on a particle size 
analyzer (N = 4). 
 Effective diameter (nm) 
Polymer N/P 10 20 30 50 
G4 PAMAM 150.7 ± 15.6 101.0 ± 11.2 89.3 ± 7.8 119.1 ± 11.5 
25-kD PEI 133.3 ± 14.1 108.1 ± 6.5 112.7 ± 9.5 105.7 ± 4.5 
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has demonstrated the importance of polymer-DNA binding [72] and endolysosomal 
pathway escape [40, 73] in gene delivery polymers.  However, we have also shown that 
PEI-mediated gene delivery does not correlate with buffering capacity [34, 74].  We thus 
hypothesize that mechanism of uptake and trafficking ultimately governs rational design 
of gene delivery vehicles.  The goal of these subsequent transfection experiments is to 
determine the interplay of clathrin and caveolae in gene delivery with proton sponge 
polymers.  We will then seek to correlate features of polymer-DNA binding with pathway 
of polyplex internalization.   
 
Endocytosis Inhibitor Toxicity  
We transfected HeLa cells in the presence of increasing drug concentrations to 
understand the interplay of trafficking mechanisms and pathways at different degrees of 
inhibition.  Drug and drug concentration ranges tested in cell experiments were: genistein, 
0-62.5 µg/mL; methyl-β-cyclodextrin, 0-12.5 mg/mL; chlorpromazine, 0-6.25 µg/mL; 
amantadine, 0-12.5 mM.  At the highest experimental drug concentrations used in 
transfection, cell viability was not significantly affected (>70%) as measured with Cell 
Titer Blue and XTT toxicity assays [3, 41, 65] (Figure 2.4). 
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Gene Delivery Activity and Uptake of PEI Polyplexes  
In vitro transfection efficiency and uptake of PEI polyplexes was tested in HeLa cells in 
the presence of anti-caveolar drugs genistein and mβCD (Figure 2.5).   
Figure 2.4.  Cytotoxicity of caveolae (genistein, methyl-β-cyclodextrin) and clathrin 
(chlorpromazine, amantadine) inhibitor drugs, and endosomal buffering drugs 
(bafilomycin, chloroquine) was determined as the normalized metabolic activity of 
HeLa cell line in the presence of  varying amounts of the drugs. Metabolic activity was 
normalized to cells grown in the absence of drugs. Red arrows indicate the highest 
concentration at which drugs were administered during transfection and uptake 
experiments. The standard deviation is shown for each data point (N = 6, error bars 
represent standard deviation). 
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Figure 2.5. Normalized in vitro transfection efficiency of PEI polyplexes at indicated N/P 
ratios in HeLa cells in the presence of endocytic inhibitors (A) genistein, and (C) methyl-β-
cyclodextrin. Luciferase activity in the cell lysates is reported as relative light units (RLU) 
divided by the mass of total protein in the lysate, and normalized to transfection efficiency 
of PEI N/P 10 in the absence of inhibitor. Uptake of YOYO-1 labeled pGL3 and PEI in 
HeLa cells in the presence of (B) genistein and (D) methyl-β-cyclo-dextrin.  Fluorescence 
values were normalized to the median fluorescence of cells transfected with N/P 10 
polyplexes in the absence of inhibitor (N=5; error bars represent standard deviation.) 
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We correlated increased concentrations of genistein with increased polyplex uptake and 
decreased gene delivery activity (Figure 2.5A, B).  Similar behavior was observed for 
PEI uptake and gene delivery activity in the presence of increasing concentrations of 
mβCD (Figure 2.5C, D).  PEI polyplexes showed a marked improvement in uptake 
(almost threefold increase at the highest N/P ratio tested), with a concomitant decrease in 
gene delivery activity. 
 
In contrast, PEI polyplex uptake was largely unaffected by the presence of amantadine 
and chlorpromazine in transfection media (Figure 2.6).  However, gene delivery 
efficiency decreased significantly with increasing concentration of these clathrin 
inhibiting drugs.   
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Figure 2.6. Normalized in vitro transfection efficiency of PEI polyplexes at indicated N/P ratios in 
HeLa cells in the presence of endocytic inhibitors (A) chlorpromazine and (C) amantadine.  
Luciferase activity in the cell lysates is reported as relative light units (RLU) divided by the mass 
of total protein in the lysate, and normalized to transfection efficiency of PEI N/P 10 in the 
absence of inhibitor. 
 
Uptake of YOYO-1 labeled pGL3 and PEI in HeLa cells in the presence of (B) chlorpromazine 
and (D) amantadine.  Fluorescence values were normalized to the median fluorescence of cells 
transfected with N/P 10 polyplexes in the absence of inhibitor (N=5; error bars represent 
standard deviation.) 
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Our flow cytometry uptake results show that PEI polyplex uptake remained unaffected 
across the range of chlorpromazine and amantadine concentrations used to inhibit 
clathrin-based endocytosis in HeLa cells.  This suggests either that 1) a clathrin-
independent pathway is entirely responsible for internalization of PEI polyplexes, or 2) 
clathrin-based endocytosis may account for a proportion of PEI polyplex uptake, but its 
inhibition may result in the promotion of clathrin-independent uptake mechanisms that 
serve to offset any resulting uptake decreases [46, 47].  Interestingly, Rejman et al. 
reported 50-70% decreases in PEI polyplex uptake in the same cell line at 
chlorpromazine concentrations twice the maximum concentration we used (5 µg/mL) [47, 
75]. 
 
In contrast to Rejman et al. and Gabrielson et al. [3], we observed decreased PEI gene 
delivery activity with increasing chlorpromazine and amantadine concentrations.   This 
phenomenon has also been reported in several cell lines when clathrin is heavily 
sequestered from the plasma membrane [76].  We note that Gabrielson et al. prepared PEI 
polyplexes at polymer/DNA weight-weight ratio 0.5, corresponding to N/P ratio 3.7.  PEI 
gene delivery activity peaked between N/P ratios 5-10 in our experiments, and we thus 
focused on this range of polyplex formulations in our analysis of polyplex trafficking.  It 
is possible that the excess of polymer present in higher N/P ratio polyplexes affects 
uptake and trafficking pathways in PEI gene delivery. 
 
If the caveolar or lipid raft pathway is responsible for successful uptake and gene delivery 
independent of the clathrin pathway as previously suggested [3, 41], we expect to observe 
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successful gene delivery activity via caveolar trafficking when transfecting in the 
presence of anti-clathrin drugs.  However, PEI gene delivery activity was completely 
abolished at 6.25 ug/mL chlorpromazine and 1.25 mM amantadine.  These data indicate 
either that 1) the clathrin pathway is entirely responsible for gene delivery, or 2) gene 
delivery may occur through a non-clathrin pathway that is dependent on active clathrin 
trafficking for successful gene delivery.  The latter is more consistent with recent reports 
in drug delivery trafficking literature [49, 77], as well as uptake results noted above.  
 
We conducted gene delivery experiments in the presence of genistein to illustrate the 
importance of active caveolar trafficking pathways in successful gene delivery, regardless 
of initial polyplex uptake mechanism.  The role of genistein as an anti-caveolar 
trafficking drug is well documented: genistein prevents actin phosphorylation necessary 
for caveolae formation at the plasma membrane [78], as well as microtubule 
polymerization that may play a role in retrograde vesicle transport [64].  Our results 
indicate increased uptake but decreased PEI gene delivery activity in the presence of 
genistein.  While Gabrielson et al. similarly reported decreased gene delivery of PEI N/P 
3.7 polyplexes in the presence of caveolae-inhibiting drugs, decreased uptake was also 
demonstrated.  In our hands, increased PEI polyplex uptake with genistein points to the 
promotion of an alternate non-caveolar internalization pathway, possibly as part of a 
compensatory mechanism regulating total flow of macromolecules into the cell, when 
caveolar based uptake is inhibited.  If this is indeed the case, such an alternate 
compensatory pathway is characterized by poor gene delivery activity in the presence of 
genistein. 
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Low MβCD concentrations have been shown to interfere with lipid-raft and caveolae-
based uptake mechanisms by sequestering cholesterol within the cell.  In our experiments, 
low MβCD concentrations did not affect the net uptake of PEI polyplexes.  At higher 
MβCD concentrations, which deplete cholesterol in clathrin-coated pits necessary for 
vesicles formation [61], an increase in net PEI polyplex uptake was observed.  Our results 
suggest that the presence of cholesterol in the plasma membrane and endocytic vesicles is 
necessary for successful PEI-based gene delivery.  Inhibiting caveolin-, lipid-raft-, or 
clathrin-based uptake mechanisms by depleting plasma membrane cholesterol does lead 
to an increase in cellular internalization of the polyplex.  However, polyplexes 
internalized by these alternate means do not exhibit efficient gene delivery. 
 
Our confocal microscopy data also indicate that PEI polyplexes associate with both 
clathrin-coated and caveolae vesicles within an hour after transfection (Figure 2.7). 
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Interfering with this putative inter-clathrin-caveolae pathway communication, as 
demonstrated by transfection in the presence of chlorpromazine, amantadine, and 
genistein, affects pathways that both need to be active for successful PEI-mediated gene 
delivery.  We thus propose that communication between active clathrin-dependent and 
Figure 2.7. Confocal Microscopy of PEI polyplexes (green) along with (A) AlexaFluor 647-
Cholera Toxin-B for staining caveolae, or (B) AlexaFluor 594-Transferrin for staining 
clathrin vesicles (red). The colocalization of the polyplexes with marker proteins is shown via 
a separate channel (yellow). The bright-field image of the corresponding cell is shown on the 
extreme left. 
 
A
  
B
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caveolin-dependent trafficking pathways is integral to successful gene delivery with PEI 
polyplexes.  Inhibition of either clathrin or caveolae based trafficking independently of 
the other results in acute decreases in PEI-based gene delivery.  Recent studies have 
pointed to Golgi complex trafficking as a contributor to this clathrin-caveolae 
communication network [79-81], showing that caveolae can relocalize to intracellular 
structures such as endosomes, endoplasmic reticulum or the Golgi complex [82-84]. 
 
It is well-known that caveolae do not undergo the same degree of endosomal acidification 
and targeting to endolysosomes as clathrin-coated vesicles [50].  However, lysosomal 
trafficking does not necessarily preclude efficient gene delivery.  Both clathrin and 
caveolar pathways can lead to effective gene delivery activity for lipoplexes and 
polyplexes [48, 49, 75, 85].  It is possible that the dependence of PEI-mediated gene 
delivery on both pathways is indeed evidence of inter-pathway trafficking.  Polyplex 
access to different pathways, or cross-trafficking, may be necessary for successful 
transfection. 
 
Gene Delivery Activity and Uptake of PAMAM Polyplexes 
In the presence of genistein, gene delivery activity with PAMAM polyplexes 
significantly decreased, although uptake was minimally affected (Figure 2.8A, B).  
Plasma membrane cholesterol depletion with mβCD increased uptake and gene delivery 
efficiency at intermediate drug concentrations, but decreased both uptake and transfection 
at the highest drug concentrations tested (Figure 2.8C, D). 
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Figure 2.8. Normalized in vitro transfection efficiency of PAMAM polyplexes at indicated N/P 
ratios in HeLa cells in the presence of endocytic inhibitors (A) genistein and (C) methyl-β-
cyclodextrin.  Luciferase activity in the cell lysates is reported as relative light units (RLU) 
divided by the mass of total protein in the lysate, and normalized to transfection efficiency of 
PAMAM N/P 10 in the absence of inhibitor. 
 
Uptake of YOYO-1 labeled pGL3 and PAMAM in HeLa cells in the presence of (B) genistein 
and (D) methyl-β-cyclo-dextrin.  Fluorescence values were normalized to the median 
fluorescence of cells transfected with N/P 10 polyplexes in the absence of inhibitor (N=5; error 
bars represent standard deviation.) 
 
 
 
  A
  
 
 
C
  
 
 
B
  
 
 
D
  
 75 
PAMAM uptake decreased markedly with increases in the concentrations of both 
amantadine and chlorpromazine (Figure 2.9).  Interestingly, we observed an increase in 
PAMAM gene delivery efficiency with small increases in clathrin-inhibiting drug 
concentration, and a reduction in efficiency to zero-drug levels at the highest drug 
concentrations.  
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Figure 2.9. Normalized in vitro transfection efficiency of PAMAM polyplexes at indicated 
N/P ratios in HeLa cells in the presence of endocytic (A) chlorpromazine and (C) 
amantadine.  Luciferase activity in the cell lysates is reported as relative light units (RLU) 
divided by the mass of total protein in the lysate, and normalized to transfection efficiency of 
PAMAM N/P 10 in the absence of inhibitor. 
 
Uptake of YOYO-1 labeled pGL3 and PAMAM in HeLa cells in the presence of (B) 
chlorpromazine and (D) amantadine.  Fluorescence values were normalized to the median 
fluorescence of cells transfected with N/P 10 polyplexes in the absence of inhibitor (N=5; 
error bars represent standard deviation.) 
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In contrast to mechanisms of PEI uptake, net PAMAM polyplex uptake appears to be 
highly dependent on active clathrin-mediated mechanisms at the cell surface, where 
uptake decreases significantly with anti-clathrin drugs.  PAMAM uptake is minimally 
affected by the presence of genistein in the transfection media.   
 
It is noteworthy that moderate cholesterol depletion that would disrupt lipid rafts and 
caveolae formation actually enhances net PAMAM uptake and gene delivery activity, 
while more severe cholesterol depletion that may also affect clathrin-vesicle formation 
decreases both.  We propose that inhibition of caveolae- or lipid raft-based uptake 
specifically by cholesterol depletion at moderate MβCD concentrations results in greater 
polyplex uptake via a clathrin route, as clathrin-coated pits are abundant across the 
plasma membrane and give rise to a majority of endocytic vesicles.    
 
Previous studies have illustrated that polyplex uptake and gene delivery activity is poorly 
correlated [49, 86].  Despite a dependence of PAMAM on clathrin-coated pits for cell 
entry, we observed an increase in gene delivery activity in the presence of moderate anti-
clathrin drug concentrations, when polyplex uptake had decreased to nearly half that of 
its drug-free control.  However, at the highest chlorpromazine and amantadine 
concentrations gene delivery activity decreased significantly.  It is possible that partially 
inhibiting clathrin internalization mechanisms resulted in a minimal compensatory 
increase in PAMAM polyplex uptake along an alternate non-clathrin pathway.  This 
alternate pathway exhibited high subsequent gene delivery activity.  We propose that this 
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alternate pathway leads to efficient gene delivery, but not when clathrin uptake 
mechanisms are fully inhibited.  
   
Similar studies from other research groups have showed that internalization of PAMAM 
complexes is mainly caveolin-independent [52, 53] in HeLa cells.  We observed a high 
degree of colocalization between PAMAM-polyplexes and transferrin ligand in our 
confocal microscopy colocalization studies (vide infra).  However, we do note that the 
subsequent trafficking of PAMAM complexes is both caveosome pathway- and 
cholesterol-dependent for successful gene delivery.  Other groups have reported similar 
findings for dendrimer-based gene delivery [87].  Saovapakhiran et al. reported a 
caveolae-dependent mechanism for uptake as well but used only the dendrimer in their 
studies [16].  As prior research has shown, the nature of the cargo and the overall 
polyplex structure can significantly alter the internalization mechanism within cells [87, 
88]. 
 
It is noteworthy that cell viability during transfections in the presence of drugs was not a 
confounding factor in our results based on toxicity assays and previous published 
research [3, 41, 41, 65].  Our study of both uptake and gene delivery activity at varied 
degrees of uptake mechanism inhibition with endocytic inhibitors provided novel insight 
into the interdependence of endocytic and trafficking pathways.  Specifically, this 
systematic method of drug study sheds light on cellular compensatory uptake 
mechanisms that occur when one uptake pathway is inhibited.  We believe that it is 
important to understand uptake mechanism compensation as the transferal of polyplexes 
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from one pathway to another in the presence of an uptake inhibitor can lead to very 
different intracellular polyplex fates.  Previous drug inhibition studies utilizing only one 
drug concentration have not demonstrated the 1) communication interplay between 
clathrin and caveolae necessary for efficient gene delivery, and 2) possibility of uptake 
compensation mechanisms that occur when one uptake pathway is inhibited. 
 
Investigation of polyplex colocalization with early stage trafficking vesicles 
Polyplex uptake and gene delivery activity studies in the presence of endocytic inhibitors 
provided insight into the cellular trafficking mechanisms involved in successful gene 
delivery.  These data were then visually corroborated by determining intracellular 
colocalization between fluorescently tagged polyplexes and vesicle-specific ligands with 
confocal microscopy.  We have tagged ligands whose uptake and intracellular trafficking 
pathways are well-documented as markers of clathrin and caveolae vesicles [89, 90].  In 
our study, cholera toxin-B is internalized at the plasma membrane via caveolae, while 
transferrin is internalized via clathrin-coated pits.  Images were taken within one hour of 
transfection and are representative of early endocytic behavior. 
 
Our confocal microscopy results indicated that PEI polyplexes are colocalized equally 
well with both caveolin and clathrin vesicles (Figure 2.8).  We conducted identical 
experiments with PAMAM polyplexes and observed similar results (Figure 2.10B).   
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These representative images were consistent with previously shown PEI and PAMAM 
polyplex uptake results (Figures 2.6B, D and 2.8B, D).  Neither PEI nor PAMAM 
polyplexes associated exclusively with either clathrin or caveolae during the 
internalization process.  Polyplexes may be internalized via both mechanisms.  This 
Figure 2.10. Confocal Microscopy of PAMAM polyplexes (green) along with (A) 
AlexaFluor 647-Cholera Toxin-B for staining caveolae, or (B) AlexaFluor 594-
Transferrin for staining clathrin vesicles (red). The colocalization of the polyplexes with 
caveolae is shown via a separate channel (yellow). The bright-field image of the 
corresponding cell is shown on the extreme left. 
 
A
  
 
B
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supports the finding that it is ultimately intracellular trafficking, rather than initial 
endocytosis at the cell surface, that affects gene delivery.  Early association of polyplexes 
with clathrin or caveolae may also be of limited importance in predicting gene delivery 
effectiveness because these pathways may not be mutually exclusive.  As discussed in the 
previous section, inhibition of one pathway may lead to overall increases in both uptake 
and gene delivery when other mechanisms are upregulated in a compensatory manner.  
Alternatively, severe inhibition of one pathway may actually lead to inhibition of the 
other as these pathways are co-dependent on mechanisms not currently understood.   
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Conclusions 
Our results have shown that the mechanisms of polyplex-mediated uptake and gene 
delivery are variable and highly dependent on the delivery vehicle.  Clathrin- and 
caveolin-mediated endocytosis are two classes of pathway trafficking that have been 
extensively researched in the past decade, but their interplay is poorly understood.  In this 
chapter we reported the dependence of 25-kD branched polyethylenimine (PEI) and 
generation 4 polyamidoamine (PAMAM) gene delivery on clathrin- and caveolar- 1) 
uptake mechanisms, and 2) intracellular trafficking, using well-characterized endocytic 
inhibitors at various concentrations to show that these pathways are mutually important 
for gene delivery across a wide range of N/P ratios in HeLa cells.   
 
As previous literature has shown, vehicle internalization at the plasma membrane, and its 
subsequent intracellular trafficking toward the nucleus, is highly specific to both vehicle 
and cell line [65].  The HeLa cell line exhibits several receptor types typically associated 
with caveolar and clathrin pathways, and possesses active clathrin- and caveolin-
dependent, and clathrin-and-caveolin-independent trafficking pathways.  We studied 25-
kD PEI and G4 PAMAM because they are representative benchmarks of the polymer and 
dendrimer classes of gene delivery vehicles [2, 15, 66, 67].  Both vehicles are 
characterized by a high density of primary and secondary amines that facilitate 
electrostatic binding with negatively charged DNA.  This binding produces well-
condensed DNA polyplexes at relatively low N/P ratios [34, 74, 91].   
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While 25 kD PEI and G4 PAMAM share similar biophysical properties, they exhibit 
different mechanisms of uptake and gene delivery.  Specifically, successful PEI-mediated 
gene delivery is dependent on both active clathrin and caveolar pathways.  In contrast, G4 
PAMAM uptake is heavily clathrin dependent, while gene delivery is caveolae dependent.  
The intracellular behavior of both these polyplexes point to the existence of trafficking 
pathways that are not mutually exclusive.  Further, compensatory uptake mechanisms 
also exist that are activated when one mechanism is inhibited, potentially increasing 
polyplex internalization even in the presence of an uptake inhibitor.  Thus, we conclude 
that rather than relying on a single pathway for successful gene delivery, PEI and 
PAMAM polyplexes depend on a constant interplay between clathrin and caveolae in 
HeLa cells. 
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Experimental 
Materials 
YOYO-1, with NHS-ester functionalized Alexa Fluor 488, Alexa Fluor 594 cholera toxin 
subunit B conjugate, and transferrin from human serum, Alexa Fluor 594 conjugate were 
obtained from Invitrogen (Carlsbad, CA).  Methyl-β-cyclodextrin was obtained from 
Roquette America, Inc. (Keokuk, IA).   Generation 4 PAMAM dendrimer, 25-kDa 
branched polyethylenimine, genistein, chlorpromazine, and amantadine were obtained 
from Sigma-Aldrich (St. Louis, MO). 
 
Cells and Plasmids 
The HeLa human cervical carcinoma cell line used in this study was a gift from Dr. 
Sandra McMasters (University of Illinois, Urbana, IL). The cells were cultured according 
to their ATCC protocols at 37 °C and 5% CO2 in Dulbecco's modiﬁed Eagle's medium 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.  
 
Luciferase plasmid pGL3 (Elim Biopharmaceuticals, San Diego, CA) carried the reporter 
gene used to assess gene delivery vehicle efficiency.  The plasmid encodes the firefly 
luciferase protein, driven by the SV40 promoter and enhancer domains.  Plasmid 
production, purification, and quality control were conducted by Elim Biopharmaceuticals. 
 
Physical characterization of ligand-polymer/DNA Polyplexes.   
Stoichiometry of Polymer-DNA Complexation. The stoichiometry of polymer-DNA 
complex formation can be observed as a reduction of mobility of the polyplexed DNA in 
 85 
agarose gel electrophoresis.  The lowest polymer/DNA ratio at which polyplexes remain 
immobile was identified as the charge-neutral polyplex.   
Ethidium Bromide Exclusion Assay.  Polyplexes were prepared using 0.7 µg DNA and 
diluted to 13 µL in 20 mM PIPES, 150 mM NaCl, and polymer then added to bring the 
total polyplex volume to 250 µL for a given polymer-DNA (N/P) ratio.  After 20 min 
polyplex incubation at room temperature, 0.35 µg ethidium bromide were added to the 
polyplexes, followed by an additional 15 min incubation.  The amount of free-DNA 
intercalated with ethidium bromide was determined on a fluorescent plate reader (Cary 
Eclipse, Palo Alto, CA) at 510Ex/595Em nm.  Readings were taken after 15 min ethidium 
bromide incubation, and again after 2 h, 4 h, 6 h, and 24 h at room temperature.  
Polyplex Sizing with Dynamic Light Scattering.  Polyplexes were prepared using 3.0 µg 
DNA diluted in 20 mM PIPES, 150 mM NaCl, and polymer then added to bring the total 
polyplex volume to 250 µL for a given polymer-DNA (N/P) ratio.  Following 20 min 
incubation at room temperature, polyplexes were transferred to a transparent cuvette and 
diluted with deionized water to a final volume of 1.8 mL.  Each sample was subjected to 
size measurement on a Brookhaven Instruments Corporation 90 Plus Particle Size 
Analyzer (Holtsville, NY) immediately after dilution, and again after 2 h, 4 h, 6 h, and 24 
h at room temperature.   
 
Polymer Buffering Capacity 
One milligram of each polymer was dissolved in 1 mL of deionized water and adjusted to 
pH 12.2 with 1 M NaOH.  The polymer solution was titrated with 5 µL aliquots of 2 M 
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HCl, and the pH was read (Accumet AB15, Hudson, MA) after each aliquot to generate a 
polymer pH buffering curve. 
 
Polyplexes/Transfections 
HeLa cells were seeded at 70,000 cells/well in 24 well plates 24 h prior to transfection. 
Polymer/pGL3 complexes were prepared at room temperature by mixing 1 mg/mL 
polymer in 150 mM NaCl, 20 mM PIPES, pH 7.2, with 1 mg/mL pGL3 in endotoxin free 
water, to achieve the desired N/P ratio.  Polyplexes were then incubated at room 
temperature for 10 min.  Prior to transfection, the growth media was replaced with serum-
free media and 50 µl of polyplexes was added to each well.  In experiments using 
endocytic inhibiting drugs, drugs were added to serum free media 30 minutes before 
transfection.  The transfection medium was removed and replaced with serum 
supplemented media 4 h post-transfection.  Luciferase expression was quantified 48 h 
post-transfection using the Promega luciferase assay system (Promega, Madison, WI).  
Luciferase activity was measured in relative light units (RLU) using a Lumat LB 9507 
luminometer (Berthold, GmbH, Germany), and was subsequently normalized by total cell 
protein using the Pierce BCA protein assay kit (Pierce, Rockford, IL) to yield RLU/mg 
protein.  All results were normalized to gene delivery activity of G4 PAMAM or PEI at 
N/P 10 in the absence of drugs.   
 
Flow Cytometry/Uptake Studies  
The protocol followed was identical as for transfections. Additionally, the pGL3 plasmid 
was tagged with intercalating dye YOYO-1 was added, at 1 molecule of dye / 100 base 
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pairs.  Two hours post-transfection, the cells were rinsed twice with 0.001% SDS in PBS 
and PBS, respectively, to remove surface-bound complexes.  Next, 100 µl of 0.25% 
trypsin in PBS was added to each well.  The cells and trypsin were allowed to incubate 
for 5 minutes before 50 µl of fetal bovine serum was added to each well.  The cells were 
then collected and stored on ice.  FACS analyses were performed on a Coulter EPICS 
XL-MCL flow cytometer (Beckman-Coulter, Fullerton, CA).  Uptake was measured 
using the following formula 
 
 
0,10
,
blanksample
yxblanksample
FF
FF


 
where  blank is autofluorescence of untreated cells 
 x = N:P ratio of sample 
 y = drug concentration 
Normalization was done by comparing the corrected fluorescence to N:P = 10 and in the 
absence of drugs 
 
Time-Lapse Live Fluorescence Microscopy 
Primary amines on both polymers were reacted with NHS-ester functionalized Alexa 
Fluor 488 in 0.1 M sodium bicarbonate buffer (pH 8.3) for 1 h. Labeled polymer was 
puriﬁed from unreacted dye by gel ﬁltration chromatography. HeLa cells were seeded at 
50,000 cells/well and grown for 2 days prior to transfection in a 35 mm μ-dish (ibidi®, 
Verona, WI, USA). Alexa-Fluor-647 conjugated Cholera-Toxin B and Transferrin were 
added just prior to adding the polymer complexes.  Labeled polymer complexes with 
pGL3 at N:P = 10 were then added to the plates and visualized with in the Multiphoton 
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Confocal Microscope Zeiss 710 for a period of 1 h at 37 ºC with a 100x oil immersion 
lens to investigate colocalization with clathrin and caveolin vesicles. The videos were 
then analyzed via Imaris©. 
 
Cytotoxicity 
Cytotoxicity of endocytosis inhibiting drugs was characterized in HeLa cells using the 
CellTiter-Blue cell viability assay (Promega, Madison, WI).  The assay measures the 
ability of live cells to metabolize resazurin into its fluorescent, reduced end-product, 
resorufin.  Briefly, cells were seeded in 96-well microplates at 2 × 104 cells/well and 
grown in medium containing 10% bovine serum and 1% penicillin-streptomycin at 37°C, 
5% CO2.  Growth medium was replaced with serum free DMEM 24 h after seeding.  
Endocytosis inhibiting drugs were added at the following concentrations: genistein, 0-
62.5 µg/mL; methyl-β-cyclo dextrin, 0-12.5 mg/mL; chlorpromazine, 0-6.25 µg/mL; 
amantadine, 0-12.5 mM.  DMEM along with inhibiting drugs were aspirated after four 
hours incubation and replaced with growth medium.  Plate was incubated for a further 20 
h.  Subsequently, 20μl of the CellTiter-Blue reagent was added to each well and 
incubated for an additional 4 h.  Absorbance was read at 570 nm. The background 
absorbance of cells killed with ethanol was subtracted from the viable cell absorbance.  
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CHAPTER 3 
Efficient Delivery of Transferrin- and Folic Acid Receptor-Targeted 
PAMAM/DNA Polyplexes is Dependent on Caveolar Trafficking in 
HeLa Cells 
 
Introduction 
Viruses have evolved to efficiently deliver DNA, often with high specificity, to target 
cells in the human body.  Synthetic gene delivery vehicles fall short of their viral 
counterparts due to both a lack of specific targeting methods and our incomplete 
understanding of the steps involved in the gene delivery pathway. 
 
Cationic polymers polyethylenimine (PEI) and polyamidoamine (PAMAM) dendrimer 
present an effective means to deliver therapeutic genes to mammalian cells in a manner 
that is non-immunogenic and targetable.  Both of these prototypical synthetic gene 
delivery vehicles are characterized by a high density of primary amines that condense and 
protect cargo DNA and provide easily modifiable moieties for receptor-specific targeting 
of these delivery vehicles.  In Chapter 2 we demonstrated that both PEI and PAMAM 
polyplexes can be internalized by clathrin- or caveolae-dependent endocytic mechanisms.  
We also showed that mechanism of trafficking, rather than initial uptake, was predictive 
of successful gene delivery.  The aim of this chapter is to target PAMAM polyplexes to 
plasma membrane receptors located in clathrin or caveolar domains, and study the effect 
of receptor-mediated endocytosis on gene delivery. 
 
Receptors for folic acid (folR) and transferrin (TfR) are overexpressed in a wide range of 
tumors and have been studied for cell-specific targeting in gene therapy.  Most 
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significantly, these two ligands are internalized through two different pathways: folic acid 
via caveolae, and transferrin via clathrin coated pits.  The goal of this project is to target 
PAMAM polyplexes to folic acid and transferrin receptors, and examine the impact of 
endocytic mechanism and intracellular trafficking on non-viral gene delivery.  We will 
use a panel of endocytic inhibitors and buffering agents to elucidate the interplay of 
clathrin, caveolae, and endosomal pH in this process. 
 
While the folic acid receptor has been noted in clathrin coated pits, it is most strongly 
associated with plasma membrane lipid rafts [1].  Its internalization via caveolae is 
hypothesized to be regulated by tyrosine kinase phosphorylation cascades, and mediated 
by phosphatidyl inositol signaling molecules present in raft regions [2].  For example, 
Protein Kinase Cα, which plays a role in SV40 and folic acid ligand internalization, is 
activated by the signaling lipid diacylglycerol (DAG).  DAG in turn is a byproduct of 
phosphatidyl inositol 4,5-bisphosphate (PIP2) cleavage.  Other research has shown that 
raft-based receptor tyrosine kinase (RTK) activity governs caveolar endocytosis [2-4].  
These RTK molecules are enriched in caveolae and cross-link in response to ligand 
stimuli.   
 
Additionally, the extracellular membrane is rich in GPI-anchored proteins (such as the 
folic acid receptor) that serve to stabilize raft domains.  Lipid raft stabilization leads to 
recruitment of Src family tyrosine kinase proteins and caveolin-1, eventually triggering 
their associated signaling pathways and endocytosis [5, 6].  It is thus not surprising that 
genistein, a tyrosine kinase inhibitor, was seen to be a potent inhibitor of caveolar 
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endocytosis both in literature and our previous work (Chapter 2).  In this study we expect 
cell treatment with genistein to significantly affect gene delivery of folic-acid targeted 
PAMAM.  Gene delivery with transferrin-targeted PAMAM should be minimally 
affected in the same experiment.  We note that the functionality and trafficking of the few 
folic acid receptors located in clathrin-coated pits have been minimally studied.  We will 
assume that they do not contribute significantly to folic acid receptor activity given their 
low proportion amongst the folic acid receptor population. 
 
Actin components of the cytoskeleton also play an important role in both lipid raft 
formation and trafficking of caveolar vesicles [1].  The cortical actin cytoskeleton tethers 
raft structures to the cytoskeletal framework and minimizes raft movement [7, 8].  This is 
in contrast to clathrin vesicle formation, which is enhanced by actin activity but not 
dependent on it [9, 10].  In caveolae, cytosolic build-up of actin facilitates the localization 
of endocytic machinery to the raft [11].  During endocytosis, actin depolymerization 
completes vesicle entry and enables further trafficking deeper into the cytosol [8, 11].  
The actin activity described here is thought to be made possible by adapter proteins SH2 
and SH3, which have been shown to be governed by tyrosine phosphorylation and are 
potentially additional targets for genistein.  The inhibitory effects of genistein on the 
caveolar pathway thus extend from initial endocytosis to late-stage actin-based trafficking. 
 
Many native and foreign ligands bind clathrin-associated receptors to mediate cell entry.  
These include transferrin, low density lipoprotein (LDL), epidermal growth factors (EGF), 
and influenza virus [12-14].  Several of these ligands are of interest in targeting specific 
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cells for drug delivery.  In particular, the transferrin ligand has been used extensively to 
study tumor-specific gene delivery as well as examine clathrin-based endocytosis [15-18].  
However, highly selective sorting along the clathrin-endosomal trafficking pathway 
means that the ligand, its receptor, and any attached cargo potentially have very 
dissimilar intracellular fates despite sharing a similar uptake mechanism.  For example, 
transferrin, the transferrin receptor, and the LDL receptor are recycled back to the cell 
surface.  At the same time LDL and EGF are directed to low pH endolysosomes for 
degradation [19, 20].  Both of these outcomes are in contrast to the influenza virus, which 
ultimately reaches the nucleus to successfully effect infection after entry via clathrin-
coated pits.  Lakadamyali et al. propose the existence of dynamic and static early 
endosome populations that vary in content, pH, and kinetics to explain this diversity of 
outcomes [21].  Despite the variety of destinations available in clathrin trafficking, it 
should be noted that sorting into the degrading lysosomal environments characteristic of 
this pathway is widely believed to be a source of inefficiency in many polymeric gene 
delivery systems [15, 22-25].  In our study, we expect internalization and transfection of 
transferrin-targeted PAMAM polyplexes to be strongly affected by drugs that sequester 
clathrin from the plasma membrane.  We also expect poor overall gene delivery from 
polyplexes that are internalized via clathrin-coated pits and trafficked to low-pH 
endolysosomes.  The beneficial effects of lysomotropic buffering drugs on gene delivery 
will be made evident in polyplexes that are ultimately directed to the endolysosome. 
 
We have previously shown that we are able to modulate DNA uptake and gene delivery 
efficiency across a range of polymer:DNA ratios by conjugating folic acid and transferrin 
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ligands to 25-kD PEI [15].  Specifically, 1) PEI, PEI-fol, and PEI-Tf polyplexes are 
processed effectively through the caveolar pathway, 2) PEI-Tf targeting enhanced gene 
delivery across a wide range of ligand:polymer ratios (0.1:1-0.5:1 w:w), and 3) PEI-fol 
targeting was only effective at suboptimal polymer:DNA and low ligand:polymer ratios. 
 
In this study we conjugated folic acid and transferrin to generation 4 PAMAM to assess 
the effect of receptor-specific targeting on dendrimer gene delivery behavior.  We studied 
gene delivery activity of the receptor-targeted vehicles in HeLa cells, and also examined 
PAMAM-DNA polyplex internalization at the cell-surface using YOYO-1 tagged DNA.  
We used caveolae- and clathrin- inhibiting drugs to determine the mechanism of 
polymer-DNA polyplex uptake, in addition to proton-pump inhibitors and buffering 
agents to determine the role of the endolysosome in targeted vehicle trafficking.   
 
Our results from Chapter 2 suggest that unmodified PEI and PAMAM are internalized 
and trafficked by different mechanisms, beginning at the cell surface.  We believe that the 
addition of ligands to these polymers alters their intrinsic uptake and gene delivery 
properties.  In addition to exploring caveolar and clathrin pathways, we also examined 
the possibility of inter-pathway sorting, a concept discussed in the previous chapter.  This 
study enabled us to draw a strong mechanistic understanding of ligand density and its 
effects on PAMAM uptake and transfection, and provided insight into the kinetics of 
ligand/receptor binding and turnover. 
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Results and Discussion 
Generation of Folic Acid Receptor Targeted PAMAM  
The reaction scheme used to conjugate folic acid to PAMAM via NHS chemistry is 
illustrated below (Figure 3.1).  
We added NHS-folate to PAMAM at varying folate:PAMAM ratios in the reaction, and 
 
Figure 3.1. Reaction scheme used to generate folic acid-targeted PAMAM. Based on the 
procedure of Gabrielson et al [15] and Guo et al [26]. 
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obtained conjugation ratios of between 0.3 to ~7 folate molecules per PAMAM.  Precise 
ligand labeling density was measured with absorption spectroscopy.   
 
Generation of Transferrin Receptor Targeted PAMAM  
The reaction scheme used to conjugate transferrin to PAMAM via heterobifunctional 
crosslinker Sulfo-KMUS is illustrated below (Figure 3.2).  
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Briefly, PAMAM was thiolated with 2-iminothiolane in PBS and purified by gel filtration 
chromatography.  Ellman’s reagent was used to quantify the presence of thiol groups.  
Transferrin protein primary amines were then activated with sulfo-KMUS to generate a 
Figure 3.2. (A) G4 PAMAM primary amines thiolation with 2-iminothiolane. (B) 
Transferrin primary amine reaction with Sulfo-KMUS and subsequent conjugation to 
thiolated PAMAM to generate transferrin-targeted PAMAM. 
B 
A 
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thiol-reactive form of the protein.  The thiol-reactive transferrin and thiolated PEI were 
then combined to generate the resulting PAMAM-transferrin product.   
 
Toxicity of PAMAM-Fol and PAMAM-Tf 
Polyamidoamine dendrimers exhibit cellular toxicity that is proportional to polymer 
concentration and dendrimer generation (i.e. molecular weight).  However, potential toxic 
effects of ligand conjugation are unknown.  We investigated the PAMAM-Fol and 
PAMAM-Tf cytotoxicity by completing a cell viability assay in HeLa cells (Figure 3.3).   
 
Conjugation of folic acid and transferrin ligands to G4 PAMAM did not significantly 
alter polymer toxicity at the ligand labeling densities and polymer concentrations tested.  
Two concentrations of polymer were tested: the first, 10.7 µg/mL, corresponding to 
 
 
A
  
 
 
B
  
Figure 3.3.  Cytotoxicity of (A) PAMAM-Fol, or (B) PAMAM-Tf polymers was determined as 
the normalized metabolic activity of HeLa cell line in the presence two concentrations of 
polymer. Polymer concentration of 10.7 µg/mL corresponds to typical in vitro transfection 
conditions at N/P ratio of 10.  Metabolic activity was normalized to cells grown in the 
absence of polymer. The standard deviation is shown for each data point (N = 6, error bars 
represent standard deviation). 
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typical polymer concentrations in serum-free media during transfection experiments (N/P 
10), and a second, 53.5 µg/mL, at five times that concentration.  The higher polymer 
concentration tested resulted in lower mean cell viability for each polymer.  However, 
viability data for both concentrations were not significantly different. 
 
Polyplex Gel Retardation 
Electrostatic interactions form the basis for the formation of PAMAM-DNA polyplexes.  
From the previous chapter, unmodified PAMAM formed the charge-neutral polyplex at a 
relatively low N/P ratio ≤ 2.  We sought to determine whether conjugation of folic acid or 
transferrin ligands to PAMAM affects this measure of polymer-DNA binding.  To 
determine the amount of polymer required to form charge-neutral polyplexes, polymer 
and plasmid were mixed at N/P ratios 0.5-4 and subjected to gel electrophoresis (Figure 
3.4).   
 
Neutral and positively-charged polyplexes remain in the loading wells, while negatively-
charged polyplexes and free DNA migrate through the gel.  The polyplex composition at 
which DNA and polyplexes do not enter the gel is defined as the charge-neutral N/P ratio, 
Figure 3.4. DNA gel retardation with PAMAM (A), PAMAM-Fol 7.167 (B) and PAMAM-Tf 
0.75 (C) polyplexes.  The polymer to DNA N/P ratio used to form each polyplex is given 
above the corresponding lane.   
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and is a measure of polymer-DNA interaction.  Receptor-targeted PAMAM with the 
highest ligand valency (PAMAM-Fol 7.167 and –Tf 0.75) were tested.   
 
While unmodified PAMAM completely retarded migration of DNA at N/P 1.25, the 
charge-neutral stoichiometry for both PAMAM-Fol 7.167 and PAMAM-Tf 0.75 was N/P 
1.5.  The presence of conjugated ligands to the PAMAM polymer minimally affected the 
charge neutral ratio N/P ~1-2.  Our subsequent gene delivery and uptake experiments 
were conducted at N/P ratio 5-20.   
 
Polyplex Sizing 
Polyplex sizes of unmodified PAMAM, PAMAM-Fol and PAMAM-Tf polyplexes in 
solution at physiological pH and ionic strength were determined by dynamic light 
scattering.  Particle sizes were approximately 250 nm for unmodified PAMAM, and 150 
nm for targeted polyplexes at N/P 10 (Table 3.1).   
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Table 3.1. Polyplex sizing immediately after formation in 20 mM PIPES, 150 mM NaCl.  
Polyplexes were prepared at N/P ratio 10 and subjected to dynamic light scattering on a 
particle size analyzer (N = 4). 
 Effective diameter  
       (nm)                                                                         (nm) 
PAMAM 240.6 ± 16.2   
PAMAM-Fol 0.343 182.5 ± 2.8 PAMAM-Tf 0.02 230.3 ± 26.2 
0.665 159.8  ± 3.9 0.05 155.1 ± 5 
0.984 149.3  ± 3.8 0.1 154.7 ± 3.5 
2.332 164.3  ± 2.8 0.2 161.6 ± 4.6 
2.992 164.8 ± 2.3 0.3 152.1 ± 4.7 
4.892 175.6 ± 5.7 0.5 146.6 ± 5.4 
7.167 195.7 ± 4.3 0.75 148.5 ± 8.7 
 
Gene Delivery Activity of PAMAM-Fol and  -Tf 
We synthesized folic-acid receptor targeted PAMAM gene delivery vehicles over a broad 
range of densities from 1 folate per 3 dendrimers to 7 folates per dendrimer.  Transferrin 
receptor-targeted dendrimers were synthesized at 1:1 transferrin to dendrimer and 
subsequently “diluted” with unmodified G4 PAMAM to 0.02-0.75 transferrin per 
dendrimer.  Characterization by absorption spectroscopy and BCA protein assay revealed 
a labeling density of one transferrin per PAMAM [26].   
 
Polyplexes were prepared in 20 mM PIPES, 150 mM NaCl, by adding polymer to pGL3 
luciferase reporter plasmid, and incubated at room temperature for 10 minutes.  We 
added polyplexes to HeLa cells in serum-free media for four hours before replacing 
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transfection media with growth media.  Gene delivery activity was quantified 24 h later 
by luminescence from cell lysates upon addition of luciferin  (Figure 3.5A, B). 
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Figure 3.5. In vitro transfection of HeLa cells with (A) PAMAM-Fol or (B) PAMAM-Tf at 
indicated N/P ratios.  Luciferase activity in the cell lysates is reported as relative light units 
(RLU) divided by the mass of total protein in the lysate, and normalized to transfection 
efficiency of unmodified PAMAM N/P 10.  In vitro transfection of HeLa cells with (C) 
PAMAM-Fol or (D) PAMAM-Tf polyplexes (N/P ratio of 10) in the presence of free ligand.  
Luciferase activity in the cell lysates is reported as relative light units (RLU) divided by the 
mass of total protein in the lysate, and normalized to transfection efficiency in the absence of 
free ligand.  (N = 5; error bars represent standard deviation.) 
 110 
Transgene expression varied with Fol and Tf density at all N/P ratios.   Gene delivery 
with each PAMAM-fol polymer was relatively constant across N/P ratios 5-20.  In 
contrast, gene delivery with the highest performing PAMAM-Tf polymers increased 
consistently with N/P ratio.  Optimal gene delivery activity in HeLa cells with receptor-
targeted PAMAM was achieved at 3 folate ligands per PAMAM and 0.05 transferrin 
ligands per PAMAM.  Receptor-targeted gene delivery activity with ligands exceeded 
that of unmodified PAMAM by five- to seven-fold at optimal ligand/PAMAM ratios.  
Higher ligand densities resulted in drastic decreases in transgene expression. 
 
Receptor-specific targeting was also demonstrated in Figure 3.5C, D.  Free ligand was 
added to the transfection media and incubated at 4 °C for 30 min before transfection at 
concentrations sufficient to block cellular receptors.  Incubation at 4 °C was performed to 
ensure that ligand bound to the receptor was not endocytosed via energy dependent 
mechanisms.  Polyplexes were subsequently added to the media and incubated at 37 ◦C 
for two hours.  If targeted polyplexes are internalized via the receptors, we expect the 
presence of free ligand will block polyplex binding to receptors.   
 
PAMAM-Fol polymers labeled on average with less than one folic acid exhibited 
unaffected gene delivery activity in the presence of free, competing folic acid ligand.  In 
the same experiment more targeted PAMAM-Fol polymers exhibited significant 40-50% 
gene delivery decreases.  Thus in our studies at least one folic acid ligand per PAMAM is 
required to achieve a measurable level of receptor binding capable of affecting gene 
delivery.  At the same time, gene delivery experiments studying PAMAM labeled with 2-
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7 folic acids (Figure 3.5A) showed nearly 7-fold increases over untargeted and 
minimally targeted PAMAM (PAMAM-Fol < 1).  From Figure 3.5C we can correlate 
folic-acid receptor specific binding with enhanced gene delivery. 
 
Highly targeted PAMAM–Tf polymers showed a similar (~50%) reduction in gene 
delivery activity in the presence of free, competing transferrin ligand.  Minimally targeted 
PAMAM-Tf 0.02-0.1 exhibited a graded decrease in gene delivery.  These minimally 
targeted PAMAM-Tf polymers generated the highest gene delivery activity in the 
absence of free ligand compared with untargeted and highly targeted PAMAM-Tf. 
 
It is interesting to observe that targeting to the folic acid or transferrin receptors (which 
are present in - and assumed to traffic through - caveolae and clathrin coated pits, 
respectively) can result in similarly enhanced gene delivery activity.  Increases in gene 
delivery activity with both targeted polymers was unexpected given that 1) the transferrin 
receptor is located in clathrin-coated pits, 2) clathrin-coated pits typically form vesicles 
that are trafficked to low-pH lysosomal compartments, and 3) passage through this 
environment is a documented source of inefficiency for polymeric gene delivery [15, 27, 
28].   
 
One explanation for the enhanced gene delivery observed for both types of targeted 
polymer is that conjugation of these ligands to PAMAM overcame trafficking barriers to 
gene delivery that are inherent to PAMAM alone.  A polyplex conjugated to folic acid or 
transferrin may traverse intracellular pathways inaccessible to ligand-free polyplexes.  
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For example, it is well-known that transferrin and its receptor are trafficked through low 
pH environments as part of its iron-release step [29, 30].  Both proteins are subsequently 
recycled to the cell surface.  It is not unreasonable to assume that while the low pH 
endosome is in fact a rate limiting step for unmodified PAMAM gene delivery, 
successful PAMAM-Tf gene delivery occurs because the transferrin ligand is not 
subjected to protease degradation as it passes through recycling compartments.  Its 
polyplex cargo, therefore, might also escape the lysosome and unpackage in the cytosol 
prior to nuclear entry. 
 
We thus surmise that increased gene delivery of PAMAM-Fol and –Tf polyplexes results 
from both cell surface receptor targeting and enhanced intracellular trafficking activity.  
Interestingly, minimally-targeted PAMAM-Tf polymers exhibited higher gene delivery 
compared with both untargeted, and more targeted, dendrimers.  Previous work has 
shown that oligomerized transferrin receptors do not undergo the relatively rapid 
transferrin and transferrin receptor recycling process [31].  They are instead selectively 
retained in long-lived recycling endocytic vesicles.  Gene delivery with high PAMAM-Tf 
labeling (0.3, 0.5, 0.75) is much more likely to facilitate the formation of oligomerized 
receptors during polyplex internalization.  The resulting oliogmerized 
polyplex/transferrin/transferrin receptor complex may be subsequently trafficked through 
atypical transferrin retention pathways that lead to less efficient gene delivery.  Thus, 
PAMAM-Tf 0.2-0.75 polyplexes demonstrate the greatest receptor specificity, but 
significantly lower gene delivery. 
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We note that despite the presence of the high molecular weight 75-kD transferrin protein 
in PAMAM-Tf polyplexes, each PAMAM-Tf polymer formed stable polyplexes with 
pGL3 plasmid, achieving the charge neutral N/P ratio comparable to that of unmodified 
PAMAM.   
 
Another noteworthy parameter is the relationship between N/P ratio and gene delivery 
activity.  In the cases of both PAMAM-Tf and PAMAM-Fol polymers, at each N/P ratio 
the relative level of gene delivery activity was similar between targeted and unmodified 
PAMAM.  In fact, in the case of each PAMAM-Fol polymer, absolute gene delivery was 
almost unchanged at all N/P ratios (5-20). 
 
In contrast, PAMAM-Tf polyplexes exhibited significant concomitant increases in gene 
delivery activity with N/P ratio.  We propose two possible explanations for this 
observation.  1) Higher polymer-DNA ratios facilitate more effective polyplex 
condensation and packaging.  Although we have shown that conjugation of transferrin to 
PAMAM does not alter the charge neutral polyplex, inherent differences between 
PAMAM-Fol and PAMAM-Tf may affect other aspects of PAMAM-Tf polyplex 
formation.  2) PAMAM-Tf polyplexes are more extensively internalized via clathrin 
coated pits and trafficked to low-pH endolysosomal compartments.  We would expect the 
hypothesized proton-sponge mechanism to play a greater role in facilitating endosomal 
escape of the PAMAM-Tf polyplex from these compartments as a prerequisite to 
successful gene delivery.  This phenomenon would explain the strong correlation 
between increasing PAMAM polymer (N/P ratio), which functions as a proton-sponge 
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and buffering agent, and gene delivery activity in polyplexes targeted to the clathrin 
pathway.   
 
At optimal ligand-polymer ratios, PAMAM-Fol polyplexes exhibited 4-7 fold increased 
gene delivery over unmodified PAMAM.  However, the composition of polymer and 
DNA (N/P ratio) in the polyplex did not appear to significantly affect gene delivery levels.  
Given that 1) we have successfully targeted PAMAM-Fol to the folic acid receptor, and 2) 
the folic acid receptor is typically associated with caveolae, we can conclude that proton-
sponge polymer buffering is not a limiting factor in gene delivery via a caveolar route.   
 
Conjugation of additional ligands to PAMAM beyond the optimal ratio decreased gene 
delivery activity at all N/P ratios tested (Figure 3.5A, B).  This holds true for both folic 
acid and transferrin receptor-targeted polymers, although receptor specificity increased 
with increasing ligand conjugation (Figure 3.5C, D).  We note that ligand conjugation 
does not affect polymer-DNA binding.  Polyplex retardation assays show that the N/P 
ratio of the charge-neutral polyplex is unaffected by conjugation of the ligand to 
PAMAM.  Compared with polymers at optimal ligand valency, it is possible that a 
greater proportion of polyplexes with non-optimal ligand/polymer ratios is routed to 
recycling endolysosomal compartments.  Thus, while additional ligands may enhance 
receptor-binding at the cell surface, gene delivery of the receptor-targeted PAMAM 
subsequently decreases as a result of less efficient intracellular trafficking.   
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Uptake of PAMAM-Fol and -Tf 
We conducted polyplex uptake experiments to quantify the relationships between 
internalization at the cell surface, gene delivery efficiency of the various targeted and 
untargeted PAMAM polymers, and impact of receptor-targeting on uptake (Figure 3.6).   
 
Intercalating dye YOYO-1 was added to DNA at a ratio of 15 nl YOYO-1 per 1 μg of 
DNA (corresponding to 1 molecule of dye per 100 base pairs) and incubated for 15 
minutes.  Polyplexes were subsequently formed from YOYO-1 tagged DNA as per 
normal transfection experiments.  Transfected cells were processed through a flow 
cytometer immediately post-transfection to determine total uptake of tagged polyplexes. 
 
Total uptake of the receptor-targeted PAMAM-Fol polyplexes differed minimally from 
that of unmodified PAMAM.  In contrast, PAMAM-Tf uptake increased with ligand 
 
 
B
  
 
 
A
  
Figure 3.6. Uptake of YOYO-1 labeled pGL3 and (A) PAMAM-Fol or (B) PAMAM-Tf 
polyplexes (N/P ratio of 10).  Fluorescence values were normalized to the median 
fluorescence of cells transfected with unmodified G4 PAMAM.  (N=5; error bars represent 
standard deviation.). 
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labeling, attaining 50-70% increases over unmodified PAMAM with the most targeted 
PAMAM-Tf polymers.  This increase in uptake is mostly likely related to receptor 
oligomerization discussed in the previous section.  We note that PAMAM-Tf 0.02-0.1 
polymers with the highest gene delivery activity were internalized at levels similar to 
unmodified PAMAM.  As reported in Chapter 2, internalization of unmodified PAMAM 
and PEI polyplexes at the cell surface was not an accurate predictor of gene delivery 
activity.  Rather, mechanisms of trafficking and, ultimately, intracellular destination of 
the polyplexes were determining factors of gene delivery activity.   
 
Transfection Following Selective Endocytic Inhibition with Small Molecule Drugs 
To determine whether clathrin or caveolar intracellular trafficking is responsible for 
successful gene delivery in folic acid- and transferrin receptor-targeted PAMAM 
dendrimers, gene delivery experiments were conducted in the presence of genistein, 
mCD, chlorpromazine, and amantadine (Figure 3.7).   
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Figure 3.7. Normalized in vitro transfection efficiency of PAMAM-Fol (A) or PAMAM-Tf (B) 
polyplexes (N/P ratio of 10) in HeLa cells in the presence of caveolae inhibitors genistein, 
50µg/mL; methyl-β-cyclodextrin, mg/mL; clathrin inhibitors chlorpromazine, 5 µg/mL; and 
amantadine, 1 mM.  Luciferase activity in the cell lysates is reported as relative light units 
(RLU) divided by the mass of total protein in the lysate.  Luciferase activity of drug-treated 
cells was normalized to cells grown in the absence of any inhibitors.  (N = 5; error bars 
represent standard deviation.) 
 
 
B 
  
 
A 
  
 118 
As discussed in chapter 2, tyrosine-kinase inhibitor genistein blocks caveolar uptake and 
trafficking by preventing actin polymerization necessary for caveosome formation.  
Methy-β-cyclodextin depletes plasma membrane cholesterol, decreasing membrane 
fluidity and disrupting lipid rafts.  Chlorpromazine and amantadine sequester clathrin 
molecules intracellularly and prevent their recycling back to the cell surface.   
 
Similar to previous work conducted by Gabrielson et al. with PEI-Fol and PEI-Tf 
transfection, our receptor targeted PAMAM polyplexes exhibited a strong dependence of 
caveolae for gene delivery.  Genistein and mBCD both significantly decreased gene 
delivery activity of all PAMAM polyplexes in HeLa cells by 50-90%.  The ability of anti-
caveolar drugs to dramatically reduce gene delivery indicates that caveolar processing 
contributes to efficient gene delivery in HeLa cells, regardless of targeted or intended 
uptake mechanism.  
 
PAMAM-Fol polyplexes with the highest gene delivery activity (PAMAM-Fol 2.332-
2.992, Figure 3.5A) were least affected by plasma membrane clathrin depletion.  The 
same is true of highly efficient but minimally targeted PAMAM-Tf (PAMAM-Tf 0.02-
0.1) polyplexes.  It is likely that these polyplexes are endocytosed and subsequently 
trafficked by a clathrin-independent (i.e. caveolar) pathway, leaving them unaffected by 
disturbances in plasma membrane clathrin.  PAMAM-Tf polyplexes with higher ligand 
valency (0.3-0.75) are more targeted to the transferrin receptor, exhibit lower gene 
delivery activity, and appear dependent on clathrin for successful gene delivery.  This is 
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consistent with previous reports on gene delivery activity of vehicles highly targeted to 
the transferrin receptor. 
 
In contrast to highly targeted, highly efficient PAMAM-Fol polymers, minimally targeted 
PAMAM-Fol (PAMAM-Fol < 1) exhibited gene delivery behavior similar to unmodified 
PAMAM.  Gene delivery with these polymers increased in the presence of 
chlorpromazine and amantadine.   We hypothesize that a proportion of these minimally 
targeted PAMAM-Fol polyplexes entered the cell and was trafficked by less efficient 
clathrin pathways under drug-free conditions.  An examination of inhibitor mechanisms 
and potential cellular responses to the drug may explain how gene delivery increases 
during clathrin depletion.  Chlorpromazine and amantadine inhibit clathrin coated pit 
formation by sequestering clathrin molecules within the cell and preventing clathrin 
recycling from coated vesicles back to the plasma membrane.  During this process, 
polyplexes may still bind non-specifically to the cell surface and be internalized via other 
mechanisms (i.e. caveolar) that lead to efficient gene delivery.  Potential upregulation of 
clathrin-independent pathways in response to inhibition of clathrin endocytosis is an 
additional factor that could contribute to gene delivery levels in excess of those seen 
under drug free conditions. 
 
PAMAM-Tf transfection in the presence of endocytic inhibitors exhibited a dissimilar 
profile to gene delivery studies by Gabrielson et al. with transferrin-receptor targeted PEI.  
In our hands, PAMAM-Tf gene delivery decreased when either clathrin or caveolae–
based pathways were inhibited.  As expected, drugs interrupting clathrin-coated pit 
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formation have a deleterious effect on transfection with PAMAM-Tf polyplexes targeted 
to the transferrin receptors located in these structures.  However, it is interesting that even 
polyplexes targeted to the clathrin-associated transferrin receptor also demonstrated a 
strong dependence on caveolar mechanisms for successful transfection.   
 
We previously highlighted the importance of caveolae for gene delivery, regardless of 
initial uptake mechanism.  This is less surprising upon further examination of the results.  
We have already demonstrated a seven-fold increase in gene delivery when transferrin is 
conjugated to PAMAM at optimal ratios.  The possibility of an alternative pathway 
leading to successful gene delivery coming into play with PAMAM-Tf transfection, 
despite initial polyplex targeting to the clathrin-based transferrin receptor, explains how 
PAMAM-Tf gene delivery can still be inhibited by genistein and mBCD.  While 
unmodified PAMAM polyplexes internalized through clathrin-coated vesicles continue to 
low pH endolysosomes, PAMAM-Tf polyplexes taken up in similar vesicles may 
undergo intracellular sorting to another mode of cellular transport with a different fate.  
We believe that this alternative pathway is a caveolar or cholesterol related mechanism. 
 
Transfection in the Presence of Chloroquine and Bafilomycin A1 
To further examine the idea of an alternate pathway that shifts cargo from clathrin 
vesicles, we tested whether avoidance of lysosomes enhanced gene delivery for these 
polymers (Figure 3.8). 
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Figure 3.8. Normalized in vitro transfection efficiency of PAMAM-Fol (A) or PAMAM-Tf (B) 
polyplexes (N/P ratio of 10) in HeLa cells in the presence of endosomal buffering agents 
bafilomycin A1, 10 nM, and chloroquine, 20 µM.  Luciferase activity in the cell lysates is 
reported as relative light units (RLU) divided by the mass of total protein in the lysate.  
Luciferase activity of drug-treated cells was normalized to cells grown in the absence of any 
inhibitors.  (N = 5; error bars represent standard deviation.) 
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Clathrin and caveolar trafficking differ in the intracellular fate and destination of their 
vesicles.  Clathrin vesicles and their cargo are believed to ultimately enter low pH 
lysosomes, while caveolar vesicles do not.  Gene delivery experiments were therefore 
conducted in the presence of the proton pump inhibitor bafilomycin A1 to determine the 
role of endosomal/lysosomal acidification in polymeric gene delivery.  The effect of 
chloroquine, an endosomal buffering agent frequently added to cells transfected using 
non-proton sponge polymers, on gene delivery with our targeted polymers was also 
assessed. 
 
We observed 20-70% decreased gene delivery in PAMAM and all targeted polymers with 
bafilomycin.  In addition to inhibiting pH declines seen in endosome-lysosome 
progression, we note that this drug has been reported to also affect structures associated 
with caveolar processing and the Golgi complex [32-34].  Due to the documented 
multiplicity of intracellular effects with bafilomycin, the significance of these findings 
lies in the relative effect the drug has on gene delivery from polymer to polymer.   
 
Unmodified PAMAM gene delivery decreased by over 65% in the presence of 
bafilomycin.  This is significantly higher than the 20% observed in some of the 
PAMAM-Tf and PAMAM-Fol polymers.  It is not unreasonable to infer from our results 
that acidification is a necessary process in PAMAM gene delivery.  Successful PAMAM 
gene delivery via the hypothesized proton sponge effect hinges upon endosomal 
acidification as a prerequisite for endosomal escape.  According to the proposed 
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mechanism, preventing endosomal acidification would remove an important step in the 
gene delivery process if the polyplex indeed is trafficked through a low pH environment. 
 
We noted an interesting correlation between bafilomycin gene delivery and drug-free 
gene delivery in receptor-targeted polymers: polyplexes exhibiting the highest gene 
delivery under drug free conditions were least affected by the drug.  The relationship 
holds true for both folic acid- and transferrin receptor-targeted polymers (PAMAM-Fol 
2.332-7.167, PAMAM-Tf 0.02-0.2).  These polymers demonstrated seven-fold 
transfection increases over unmodified PAMAM (Figure 3.5), yet exhibited only a 20% 
decline in the presence of bafilomycin.  In contrast, PAMAM-Fol 0.343-0.984 and –Tf 
0.3-0.75 polymers, whose gene delivery efficiency was not significantly different from 
that of PAMAM, exhibited ~70% decreases when transfected with bafilomycin.  We 
suggest that the effects of bafilomycin on gene delivery point to the existence of efficient 
gene delivery pathways that are un- or minimally acidified (e.g. caveolar), and thus less 
likely to be interrupted by proton-pump inhibition.  Gene delivery by highly targeted 
PAMAM-Fol, or minimally targeted PAMAM-Tf, appears to occur via these pathways.  
As a result, such polyplexes appear relatively independent of clathrin depletion and 
vesicle acidification. 
 
Chloroquine is a lysosomotropic drug that buffers lysosome pH, intercalates DNA and 
inhibits nuclease degradation [35, 36].  Intracellular concentrations of chloroquine have 
been shown to reach 5 mM when the drug is present in the extracellular medium at 20 
µM [37].  Its benefits in polymeric gene delivery are two-fold: 1) to facilitate endosomal 
 124 
escape of polyplexes formed using non proton sponge vehicles, and 2) preserve plasmid 
DNA during the intracellular trafficking process.  In our experiments with PAMAM-Tf 
and PAMAM-Fol, we expected the advantages of chloroquine buffering attributes to be 
masked in polyplexes that already function as proton sponges, or are trafficked through 
non-acidified vesicles [1, 38, 39].  In the latter case vesicle acidification is neither a 
source of gene delivery inefficiency nor a prerequisite for endosomal escape of proton-
sponge vehicles. 
 
Unmodified PAMAM gene delivery increased 40% in the presence of chloroquine.  We 
believe that a significant proportion of PAMAM polyplexes enter cells via clathrin-
coated pits and are trafficked to low-pH endolysosomes (Chapter 2).  Chloroquine 
buffering in this environment, coupled with enhanced nuclease resistance, most likely 
contributed to higher PAMAM transfection. 
 
PAMAM-Fol gene delivery activity with chloroquine displayed minimal (5-40%) 
increases over drug free conditions.  This result is similar to gene delivery with 
unmodified PAMAM in the same experiment.  For comparison, Gabrielson et al. also 
demonstrated ~25% increases in PEI gene delivery when chloroquine was used [15].  We 
attributed these slight increases in average gene delivery in the presence of chloroquine to 
both the DNA-protecting attribute of the drug and its buffering qualities.  In PAMAM-
Fol 2.332 and 2.998 transfection – two polymers that we have shown optimally targeted 
to the caveolar pathway and minimally trafficked through acidified clathrin routes – 
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chloroquine enhanced gene delivery a mere 5%.  These data suggest the dominant effect 
of chloroquine in the transfection process lies in its endosomal buffering capacity.   
 
In contrast to Gabrielson et al.’s work with PEI-Tf polymers, chloroquine dramatically 
decreased gene delivery of transferrin-receptor targeted PAMAM.  We had previously 
expected PAMAM-Tf to be trafficked via clathrin pathways and hence dependent on a 
proton-sponge mechanism for endosomal escape.  Indeed, previous research has shown 
that the transferrin receptor and its ligand are trafficked through low-pH intracellular 
compartments [29, 40].  This is a necessary step for the successful release of iron from 
transferrin.  If PAMAM-Tf gene delivery progressed simply through an acidified clathrin 
pathway leading to lysosomes, the presence of chloroquine during PAMAM-Tf gene 
delivery should have resulted in higher transfection via the proton-sponge effect.  
However, the transferrin receptor is different from other cell-surface receptors that 
release their cargo (e.g. LDL) to sorting endosomes before the receptor alone is recycled 
to the cell surface [30].  Instead, the entire transferrin-receptor complex is recycled 
(anterograde) to the cell surface.  The round trip of the transferrin molecule through 
cellular sorting milieu presents additional pathways for gene delivery not available 
through the unidirectional clathrin-lysosomal pathway. 
 
The transferrin molecule’s modified trafficking route is potentially responsible for high 
levels of gene delivery seen in moderately targeted PAMAM-Tf 0.02-0.2.  As transferrin 
and the transferrin receptor are sorted out of the endosome, the associated PAMAM-Tf 
polyplex could be released into the cytosol, where unpackaging occurs.  Cargo plasmid 
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DNA may subsequently be trafficked along a different pathway to the nucleus to 
complete gene delivery.  PAMAM-Tf polymers effecting gene delivery by this proposed 
route would also bypass extended lysosome internment, accounting for the minimal effect 
of both bafilomycin and chloroquine seen on the gene delivery process of PAMAM-Tf 
0.02-0.2. 
 
PAMAM-Tf with higher ligand valency (0.3-0.75) may be subject to receptor 
oligomerization and deposition in endosomal retention vesicles (pH 6.4) distinct from 
lysosomes [31].  According to Marsh et al., multivalent transferrin molecules and their 
associated oligomerized receptors induce a lumenal retention signal in early endosomes.  
These agglomerations are retained inside the cell on average four times longer than 
individual transferrin, gradually progressing through sorting endosomes (pH 6) where 
recycling occurs.  Thus the main differences between normal transferrin and multivalent 
transferrin endocytic processing appear to be 1) the duration of residence as well as 2) pH 
within the different sorting/recycling vesicles.  This extended retention of multivalent 
transferrin could be responsible for the lower gene delivery activity seen in PAMAM-Tf 
0.3-0.75 than PAMAM-Tf 0.02-0.2 (under drug free conditions).  As the transferrin iron 
release and transferrin recycling processes appear to be dependent on pH signaling cues, 
the presence of intravesicular chloroquine is likely to interrupt normal transferrin ligand 
trafficking.  PAMAM-Tf 0.3-0.75 polyplexes traversing such a retention and sorting 
endosome cascade might also be affected, explaining the decreased gene delivery of these 
polyplexes to ~30% of drug-free controls. 
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Unmodified PAMAM/DNA polyplexes, by comparison, are most likely trafficked via 
acidified pathways to the endolysosome.  In this scenario cytosolic release and successful 
gene delivery are limited by the proton-sponge mechanism.  Our chloroquine experiments 
suggest that PAMAM and PAMAM-Tf polymers effect gene delivery via very different 
pathways.  Degree of acidification is identified as a significant difference between the 
two routes.   
 
Uptake Following Selective Endocytic Inhibition with Small Molecule Drugs 
Uptake studies of PAMAM-Fol and –Tf polyplexes were conducted with YOYO-1 
tagged DNA in HeLa cells to determine correlation between intracellular trafficking and 
gene delivery (Figure 3.7) with mechanism of internalization (Figure 3.9).  The same 
drug concentrations were used for gene delivery and uptake studies. 
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Figure 3.9. Normalized 
median fluorescence of 
HeLa cells transfected 
with YOYO-1 
labeled pGL3 and (A) 
PAMAM-Fol, or (B) 
PAMAM-Tf polyplexes 
(N/P ratio of 10) in the 
presence of caveolae 
(genistein, 50 μg/ml; 
methyl-β-cyclodextrin, 
10 mg/ml) and clathrin 
(chlorpromazine, 5 μ
g/ml; amantadine, 1 
mM) inhibitors. 
Fluorescence values 
were normalized to the 
median fluorescence of 
cells grown in the 
absence of drugs. (N = 
5; error bars represent 
standard deviation.) 
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In these flow cytometry experiments, net uptake of unmodified PAMAM minimally 
altered by the presence of either clathrin- or caveolar-inhibiting drugs.  PAMAM gene 
delivery experiments (previous section) showed significantly decreased transfection with 
genistein and mBCD, and increased transfection with chlorpromazine and amantadine.  
This apparent contradiction suggests that net uptake is not necessarily an accurate 
indicator of gene delivery efficiency.   
 
There are several caveats to be taken into account when interpreting flow cytometry data.  
As previously discussed, polyplexes delivered in the presence of endocytic inhibitors may 
still bind non-specifically to the cell surface and be internalized via other mechanisms.  
Further, interruption of one uptake mechanism may induce the upregulation of another, 
resulting in compensatory uptake of polyplexes that offsets any decreases in 
internalization that may have otherwise been observed. 
 
We have also shown that net uptake of polyplexes can vary greatly with drug 
concentration (Chapter 2) – another reason uptake data should be interpreted with care.  
For example, PAMAM polyplex uptake increased at moderate concentrations of genistein 
or mβCD.  Uptake subsequently declined to levels comparable to baseline at significantly 
higher drug concentrations (Figure 2.8).  Again, we believe this phenomenon to be the 
result of a dynamic cellular endocytic network that regulates different mechanisms of 
uptake, capable of adjusting to the increasing action of endocytic inhibitors.  In Figure 
3.9, PAMAM uptake was only assessed at one drug concentration.  Yet the reader might 
infer from the data in this chapter alone that the endocytic inhibitors selected had very 
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minimal effect on the uptake of the unmodified PAMAM polyplexes.  Taking into 
account work from the previous chapters, we believe PAMAM is capable of being 
internalized via clathrin or caveolar pathways.  Inhibiting one pathway at high inhibitor 
concentrations may simply result in polyplex uptake via another mechanism.  However, 
we note that only interruption of the caveolar pathway results in dramatically decreased 
gene delivery. 
 
Uptake of folic-acid receptor-targeted polyplexes with endocytic inhibitors more closely 
resembled gene delivery profiles of the same polymers with drugs at these concentrations.  
Internalized PAMAM-Fol polyplexes decreased in the presence of caveolae-inhibiting 
drugs, but slightly increased in the presence of clathrin-inhibiting drugs.  Compared with 
unmodified PAMAM, these PAMAM-Fol data are consistent with a greater proportion of 
polyplexes entering the cell via a caveolar mechanism. 
 
In contrast, uptake of PAMAM-Tf polyplexes decreased notably in the presence of both 
clathrin- and caveolae-inhibiting drugs.  This behavior mirrored that of PAMAM-Tf gene 
delivery with endocytic inhibitors.  Decreased PAMAM-Tf uptake during clathrin 
inhibition is consistent with the expected mechanism of receptor-mediated internalization.  
Most importantly, the striking difference in relative uptake between PAMAM-Fol and 
PAMAM-Tf polymers with chlorpromazine and amantadine indicates that the two 
receptor-targeted polymers are in fact being internalized through different mechanisms.   
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It is still surprising that inhibition of caveolar actin polymerization with genistein and 
cholesterol depletion with mβCD resulted in decreased PAMAM-Tf uptake.  We offer 
two explanations for this observation.  The first is that cholesterol contributes to 
membrane fluidity required for vesicle formation.  Acute cholesterol depletion from the 
membrane can inhibit clathrin-coated pit budding, and specifically reduce transferrin 
trafficking by 85% [41, 42].  The second is that genistein, in addition to its putative role 
as a tyrosine kinase inhibitor of caveolar budding [43], also depolymerizes microtubules 
at high concentrations in certain cell lines [44].  Microtubules and actin are both key 
components of the cytoskeletal framework that play a role in endocytosis.  It is not 
unlikely that such an interruption would affect endocytosis involving relatively large 
protein (75-kD transferrin) and polyplex aggregates. 
 
Our flow cytometry results not only shed light on the relationship between uptake and 
gene delivery of receptor-targeted polymers, but also provide additional insight into the 
limitations of studying uptake as a parameter governing gene delivery.  While our uptake 
results somewhat reflect those of gene delivery under the same drug conditions (Figure 
3.7), we believe that subsequent intracellular trafficking rather than endocytosis at the 
plasma membrane is still the determining factor in how polyplexes deliver their cargo to 
the nucleus to effect gene delivery. 
 
Conclusions 
The results presented in this chapter show that caveolar trafficking is a key step in 
successful HeLa cell gene delivery with polymers.  PAMAM can enter HeLa cells 
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through both caveolae and clathrin mechanisms.  However, caveolae are ultimately 
responsible for successful transfection, as PAMAM polyplexes targeted to both the folic 
acid- and transferrin receptors are effective only when caveolae were uninhibited.  It is 
well-known that clathrin coated vesicles and caveolae have origins in separate domains in 
the plasma membrane and do not share similar intracellular fates.  Vesicle acidification 
characterizes clathrin vesicles that are ultimately destined to the endolysosome.  However, 
this investigation of receptor-mediated gene delivery has demonstrated that intracellular 
sorting and recycling vesicles enable polyplex cargo to traverse multiple pathways in the 
course of trafficking. 
 
The effects of bafilomycin and chloroquine on gene delivery indicate that PAMAM 
functions as a proton-sponge polymer.  Evidence that unmodified PAMAM relies on the 
proton sponge hypothesis for endosomal escape is visible in gene delivery that decreased 
during transfection with bafilomycin, but increased with chloroquine.  Bafilomycin 
prevents the drop in endosomal pH necessary to initiate the osmotic swelling that 
precedes polyplex escape from the cytosol.  A greater proportion of polyplexes are thus 
less likely to deliver their genetic cargo to the nucleus.  Conversely, chloroquine 
facilitates endosomal buffering and expedites the polyplex endosomal escape process.   
 
We targeted PAMAM to the transferrin and folic acid receptor by attaching ligands to the 
polymer.  In general, polyplexes displaying a greater number of ligands exhibited greater 
receptor-specificity.  However, receptor specificity did not necessarily entail greater gene 
delivery activity.  Highly targeted PAMAM-Fol polymers were more dependent on 
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caveolae for uptake and gene delivery than unmodified PAMAM and PAMAM-Tf.  
PAMAM-Fol 2.332-4.892 (optimal folate ligand valency) polyplexes were minimally 
affected by bafilomycin and chloroquine, inhibitors of vesicle acidification.  This further 
supports the initial observation that the folic acid receptor and its cargo are trafficked via 
non-acidified caveolar pathways that lead to successful transfection. 
 
PAMAM-Tf polyplexes demonstrated a dependence on clathrin for both uptake and gene 
delivery, as expected.  Surprisingly, caveolae interruption also inhibited both of these 
steps.  We believe PAMAM-Tf is internalized via clathrin coated pits, and possibly to a 
lesser extent, caveolae.  However, PAMAM-Tf passage through sorting vesicles may 
enable transfer to other pathways.  This would explain active caveolae as the rate-limiting 
requirement for successful transfection with PAMAM-Tf.  Also noteworthy are the 
potential gains in efficiency seen in some PAMAM-Tf (0.02-0.2) polymers over 
untargeted PAMAM.  These are polymers whose 1) uptake is most affected by caveolae 
inhibitors, 2) gene delivery least affected by clathrin inhibitors, and 3) gene delivery 
minimally changed by endosomal buffering agents.  The unique intracellular round-trip 
recycling of the transferrin ligand and receptor, and by extension its polyplex cargo, most 
likely accounts for the unexpected improvements in gene delivery efficiency seen when 
we conjugate small amounts of the transferrin ligand to PAMAM. 
 
Thus, our experiments with receptor-targeted and untargeted polymers in Chapters 2-3 
indicate that caveolar, but not clathrin, processes yield effective gene delivery activity in 
HeLa cells, irrespective of the initial mode of cell entry. 
 134 
 
Experimental 
Cells and Plasmids 
The HeLa human cervical carcinoma cell line used in this study was a gift from Dr. 
Sandra McMasters (University of Illinois, Urbana, IL). The cells were cultured according 
to their ATCC protocols at 37 °C and 5% CO2 in Dulbecco's modiﬁed Eagle's medium 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.  
 
Luciferase plasmid pGL3 (Elim Biopharmaceuticals, San Diego, CA) carried the reporter 
gene used to assess gene delivery vehicle efficiency.  The plasmid encodes the firefly 
luciferase protein, driven by the SV40 promoter and enhancer domains.  Plasmid 
production, purification, and quality control were conducted by Elim Biopharmaceuticals. 
 
Generation of Folic Acid Conjugated PAMAM 
Folic acid was conjugated to PAMAM according to procedures previously described [15, 
45].  Folic acid was dissolved in dimethylsulfoxide with a 1.1 molar excess of both 
Nhydroxysuccinimide (NHS) and N,N'-Dicyclohexylcarbodiimide (DCC) and stirred 
overnight at 25 ºC.  The dicyclohexylurea precipitate was filtered and removed the 
following day.  The NHS-folate product was collected, quantified by ultraviolet 
absorption at 363 nm and used immediately.  To conjugate the NHS-folate product to 
PAMAM, both were dissolved 0.1 M sodium bicarbonate buffer (pH 8.3) at the desired 
labeling ratio at stirred overnight at 25 ºC.  The product was purified from reactants by 
gel filtration chromatography (PD-10, GE Healthcare, Uppsala, Sweden) and 
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characterized using a ninhydrin assay (PAMAM quantification) and ultraviolet 
absorption at 363 nm (folate quantification). 
 
Generation of Transferrin Conjugated PAMAM 
Human apo-transferrin was conjugated to G4 PAMAM using the heterobifunctional 
crosslinker sulfo-KMUS.  PAMAM was thiolated with 2-iminothiolane in PBS and 
purified by gel filtration chromatography (PD-10, GE Healthcare, Uppsala, Sweden).  
Ellman’s reagent was used to quantify the presence of thiol groups.  PAMAM was 
quantified using a ninhydrin assay.  Transferrin protein primary amines were then 
activated with sulfo-KMUS to generate a thiol-reactive form of the protein.  Transferrin 
and sulfo-KMUS were added at a molar ratio of 1:1.5 and stirred at 25 ºC for 4 hours.  
Activated transferrin was purified by gel filtration chromatography (PD-10, GE 
Healthcare, Uppsala, Sweden) and quantified using BCA assay. The thiolreactive 
transferrin and thiolated PEI were then combined at a 1:1 molar ratio in PBS with 5 mM 
EDTA and stirred overnight at 25 °C.  The resulting PAMAM-transferrin product was 
purified using a 75,000 MWCO centrifugal filter (Millipore, Temecula, CA).  PAMAM 
concentration in the PAMAM-Tf retentate was quantified using a ninhydrin assay, and 
that of transferrin using a BCA protein assay.  PAMAM-Tf thus synthesized at a ratio of 
approximately 1:1 was loaded with iron by adding two molar equivalents of ferric citrate 
to the polymer, and subsequently diluted in unmodified PAMAM to achieve the desired 
ligand presence in polymer solution. 
 
 
 136 
Physical Characterization of Ligand-Polymer/DNA Polyplexes.   
Stoichiometry of polymer-DNA complexation. The stoichiometry of polymer-DNA 
complex formation can be observed as a reduction of mobility of the polyplexed DNA in 
agarose gel electrophoresis.  The lowest polymer/DNA ratio at which polyplexes remain 
immobile was identified as the charge-neutral polyplex.   
Polyplex Sizing with Dynamic Light Scattering.  Polyplexes were prepared using 3.0 µg 
DNA diluted in 20 mM PIPES, 150 mM NaCl, and polymer then added to bring the total 
polyplex volume to 250 µL for a given polymer-DNA (N/P) ratio.  Following 20 min 
incubation at room temperature, polyplexes were transferred to a transparent cuvette and 
diluted with deionized water to a final volume of 1.8 mL.  Each sample was subjected to 
size measurement on a Brookhaven Instruments Corporation 90 Plus Particle Size 
Analyzer (Holtsville, NY) immediately after dilution, and again after 2 h, 4 h, 6 h, and 24 
h at room temperature.   
 
Polyplexes/Transfections 
HeLa cells were seeded at 70,000 cells/well in 24 well plates 24 h prior to transfection. 
Polymer/pGL3 complexes were prepared at room temperature by mixing 1 mg/mL 
polymer in 150 mM NaCl, 20 mM PIPES, pH 7.2, with 1 mg/mL pGL3 in endotoxin free 
water, to achieve the desired N/P ratio.  Polyplexes were then incubated at room 
temperature for 10 min.  Prior to transfection, the growth media was replaced with serum-
free media and 50 µl of polyplexes was added to each well.  In experiments using 
endocytic inhibiting drugs, drugs were added to serum free media 30 minutes before 
transfection.  The transfection medium was removed and replaced with serum 
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supplemented media 4 h post-transfection.  Luciferase expression was quantified 48 h 
post-transfection using the Promega luciferase assay system (Promega, Madison, WI).  
Luciferase activity was measured in relative light units (RLU) using a Lumat LB 9507 
luminometer (Berthold, GmbH, Germany), and was subsequently normalized by total cell 
protein using the Pierce BCA protein assay kit (Pierce, Rockford, IL) to yield RLU/mg 
protein.  All results were normalized to gene delivery activity of G4 PAMAM or PEI at 
N/P 10 in the absence of drugs.   
 
Flow Cytometry/Uptake Studies  
The protocol followed was identical as for transfections. Additionally, the pGL3 plasmid 
was tagged with intercalating dye YOYO-1 was added, at 1 molecule of dye per 100 base 
pairs.  Two hours post-transfection, the cells were rinsed twice with 0.001% SDS in PBS 
and PBS, respectively, to remove surface-bound complexes.  Next, 100 µl of 0.25% 
trypsin in PBS was added to each well.  The cells and trypsin were allowed to incubate 
for 5 minutes before 50 µl of fetal bovine serum was added to each well.  The cells were 
then collected and stored on ice.  FACS analyses were performed on a Coulter EPICS 
XL-MCL flow cytometer (Beckman-Coulter, Fullerton, CA).  Uptake was measured 
using the following formula 
 
 
0,10
,
blanksample
yxblanksample
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
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where  blank is autofluorescence of untreated cells 
 x = N:P ratio of sample 
 y = drug concentration 
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Normalization was done by comparing the corrected fluorescence to N:P = 10 and in the 
absence of drugs 
 
Cytotoxicity 
Cytotoxicity of endocytosis inhibiting drugs was characterized in HeLa cells using the 
CellTiter-Blue cell viability assay (Promega, Madison, WI).  The assay measures the 
ability of live cells to metabolize resazurin into its fluorescent, reduced end-product, 
resorufin.  Briefly, cells were seeded in 96-well microplates at 2 × 104 cells/well and 
grown in medium containing 10% bovine serum and 1% penicillin-streptomycin at 37°C, 
5% CO2.  Growth medium was replaced with serum free DMEM 24 h after seeding.  
Endocytosis inhibiting drugs were added at the following concentrations: genistein, 0-
62.5 µg/mL; methyl-β-cyclo dextrin, 0-12.5 mg/mL; chlorpromazine, 0-6.25 µg/mL; 
amantadine, 0-12.5 mM.  DMEM along with inhibiting drugs were aspirated after four 
hours incubation and replaced with growth medium.  Plate was incubated for a further 20 
h.  Subsequently, 20μl of the CellTiter-Blue reagent was added to each well and 
incubated for an additional 4 h.  Absorbance was read at 570 nm. The background 
absorbance of cells killed with ethanol was subtracted from the viable cell absorbance. 
Each experiment was repeated six times at each drug concentration. 
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CHAPTER 4 
 
Elucidating Gene Delivery Mechanism of Integrin Receptor-Targeted 
PAMAM Polyplexes 
 
Introduction 
Integrins are cell adhesion receptors that mediate cell-extracellular matrix (ECM) and 
cell-cell interactions.   They also function in signaling by responding to external factors 
such as hormones and changes in the ionic environment, and play an important role in the 
cytoskeletal organization of cells [1-3].  By regulating both cell-surface adhesion and the 
signaling that governs this adhesion processes, integrins are pivotal in cancer cell 
invasion and migration.   
 
Integrin is a transmembrane glycoprotein heterodimer comprising α and β subunits.  
Eighteen alpha and eight beta subunits exist, which combine to form 24 wild-type 
integrin proteins.  Eight of the 24 integrin heterodimers recognize the arginine-glycine-
aspartic acid (RGD) sequence [4].  Under physiological conditions, exposed RGD 
sequences in ECM proteins, such as collagen and laminin, provide abundant attachment 
surfaces for the integrin receptor. 
  
The integrin family of proteins has been found to be upregulated in many malignancies 
[5-7].  It is well known that activated integrins are critical components in many phases of 
tumorigenesis.  They regulate important cancer-related phenomena consistent with their 
extracellular matrix binding properties, such as invasion, extravasation, metastasis, and 
angiogenesis.  The association of the integrin family with serine proteases and 
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metallomatrix proteases further highlights its role as a regulator of tumor cell invasion 
and angiogenesis.  
 
In the cancer setting, great interest is fueled by the potential of integrin-receptor targeting 
for clinical application.  Overexpression of integrin receptors in vascular tissue and 
tumors has been the focus of receptor-mediated imaging and drug delivery development 
efforts [8-16].  For the past two decades researchers have explored gene delivery options 
using the RGD ligand for the treatment of cancer and other malignancies [17-25].   
 
Outside of cancer, cystic fibrosis (CF) is one of the most heavily researched single-gene 
Mendelian disorders in the gene therapy field [26-29].  Integrin receptors are highly 
expressed in airway epithelial cells [30, 31], and include the αVβ3 protein that binds 
vitronectin.  The goal of CF gene therapy is to reconstitute expression of the CF 
transmembrane conductance regulatory protein in pulmonary epithelia.  Most efforts have 
focused on direct, nebulized administration of the receptor-targeted vector and its cargo 
into the airway [32, 33].  Discovery that certain members of the integrin family are 
expressed almost exclusively in a few highly specialized tissues, abundant throughout the 
human airway epithelia in vivo, has further spurred research into developing receptor-
specific vectors for this application. 
 
Nonviral vectors are often modified with small-molecule, peptide or protein ligands to 
enhance targeting and increase their overall gene transfer efficiency.  Minimized protein 
aggregation is an additional advantage of integrin-mediated gene delivery.  Compared 
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with larger protein ligands (such as PAMAM-Tf), RGD (500 Da) is less likely to be 
constrained by the size of the polyplex, which will minimize protein aggregation effects 
typical of polyplexes in serum [34].  In our study we describe gene transfer to ovarian 
epithelial cells with a PAMAM-DNA polyplex containing the integrin-binding RGD 
domain.  PEI and PAMAM have been previously modified with ligands [35-46] to target 
receptors, with the chemistries typically taking advantage of amine groups on the 
polymer.  Our synthesis of PAMAM-RGD conjugates cyclic RGD-containing peptides to 
activated primary amines on the PAMAM dendrimer.  As a result, we expect ligands to 
be randomly distributed over the PEI-DNA polyplex [47].   
 
Previous gene delivery studies with RGD-conjugated polymers indicated a strong 
dependency on cell-surface expression of the αVβ3 receptors for success, and results have 
shown that transfection occurring via the integrin-receptor specific pathway leads to high 
gene delivery activity.  Ng et al. demonstrated that polyplexes targeted to the receptor 
resulted in either 5.4- or 35-fold increase in gene transfer efficiency over unmodified 
polyplexes, depending on whether receptor expression was induced in HeLa cells [47]. 
 
Despite the extensive research conducted on RGD gene delivery, very little is known 
about the endocytic mechanism of the ligand and its subsequent intracellular trafficking 
as it relates to the gene delivery process [31].  The relative contribution of clathrin- and 
caveolae-mediated uptake in delivery of integrin-targeted polymeric vectors is only 
minimally explored in the literature [12].  In light of our results published previously [48, 
49] and described in Chapter 3, we propose that vector design for gene transfer, therefore, 
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must take into account the endocytic processing pathway resulting from integrin-
mediated endocytosis.  In this chapter, we specifically characterized dependence of 
PAMAM-RGD gene delivery on uptake mechanism and trafficking, as they relate to 
clathrin and caveolar endocytic pathways.   
  
Results and Discussion 
Generation of αvβ3 Integrin Receptor-Targeted PAMAM 
PAMAM-RGD vehicles were synthesized and characterized following an established 
protocol [50].  The reaction scheme used to conjugate RGD to PAMAM is illustrated 
below (Figure 4.1).  
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Cyclic RGD peptides were reacted with Sulfo-LC-SPDP-activated PAMAM 
intermediates to produce PAMAM-RGD polymers via a disulfide bond.  Final PAMAM-
RGD products were characterized with ninhydrin to determine amine concentration and 
UV-Vis (absorbance 275 nm) to determine peptide concentration.  Conjugates were 
prepared containing 0.31, 0.77, 1.13, 1.81, 2.25 and 4.6 peptides per PAMAM.  Target 
ligand conjugation was based on existing literature [50, 51] as well as our previous 
Figure 4.1 Reaction scheme used to generate RGD-conjugated PAMAM . 
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synthesis of PAMAM-Fol (Chapter 3), given that folic acid and the cyclic RGDfC 
peptide shared similar molecular weights.   
 
Cell Line Characterization 
The integrin receptor αvβ3 is expressed in both cancerous and normal human cell lines.  
We selected four cell lines to study PAMAM-RGD gene delivery: Chinese Hamster 
Ovary (CHO), HepG2, HeLa, and SiHa.  CHO cells are non-human mammalian cells that 
express the integrin family of receptors, but not αvβ3.  HeLa and HepG2 cells are well-
characterized human epithelial carcinomas of the cervix and liver, respectively.  Like 
HeLa cells, SiHa cells are from a cervical epithelial carcinoma, and are also known to 
highly express the αvβ3 integrin receptor [52, 53].  The presence of αvβ3 in our cells was 
determined by ELISA and normalized by total cell protein with BCA assay (Table 4.1).  
Abundance of clathrin and caveolae in these cells was determined by Western blot 
against the clathrin heavy chain (CLTC) or caveolin-1 (CAV-1) proteins (Figure 4.2).  
As we have previously used HeLa cells as our model cell line in the previous two 
chapters, the amount of αvβ3, clathrin heavy chain, and caveolin-1 protein detected in the 
four cell lines here are normalized to that of HeLa cells for comparison. 
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In our cultures neither CHO nor HepG2 cells expressed measurable quantities of the αvβ3 
receptor.  HepG2 cells also expressed undetectable levels of caveolin-1.  The clathrin 
Table 4.1. Relative αvβ3, clathrin, and caveolin protein content in each cell line 
normalized to that of HeLa cells.   
Cell Line Normalized αvβ3  
(pg/ug total cell protein) 
n=3 
Clathrin Heavy 
Chain 
(relative density) 
Caveolin-1 
(relative density) 
CHO 0 0.34 2.09 
HepG2 0 0.54 0 
HeLa 1 1 1 
SiHa 2.09 0.37 1.6 
CHO SiHa 
HeLa HepG2 
HepG2 CHO SiHa HeLa 
 
 
B
Figure 4.2. Western blot assay for (A) clathrin heavy chain and (B) caveolin-1 protein in 
HeLa, HepG2, SiHa, and CHO cells. 
 
 
A
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heavy chain protein was most highly expressed in HeLa cells, and has been a model cell 
line in our previous studies of clathrin-dependent endocytosis.  Consistent with previous 
literature, HeLa and SiHa cells expressed the αvβ3 receptor, with SiHa cells having over 
two-fold excess in receptor density over HeLa cells.  We recognize that integrin 
expression, given the receptor’s important role in cell adhesion and signaling, can be 
induced in a situation dependent manner.  For that reason consistent growth conditions of 
each cell line were maintained throughout the duration of the study.  Adherent cells were 
cultured in T75 flasks until 85% confluency before being split at 1/5 ratios.  This was 
performed biweekly until passage 15.  New cells were subsequently grown from stock.   
 
Polymer Cytotoxicity 
Polyamidoamine dendrimers exhibit cellular toxicity that is proportional to concentration 
and generation (i.e. molecular weight).  Gene delivery protocols have been established 
for PAMAM that effect successful gene delivery with minimal toxicity in a variety of cell 
lines [50, 51, 54-60].  We seek to demonstrate that our ligand-conjugated PAMAM 
polymers are minimally toxic to the four chosen cell lines under experimental conditions.  
We investigated PAMAM-RGD cytotoxicity by completing viability assays in each cell 
at two polymer concentrations.  The first polymer concentration tested corresponded to 
typical polymer concentrations in serum-free media during transfection experiments (N/P 
10, 10.7 µg/mL polymer).  The second concentration was set at five times (53.5 µg/mL) 
that of the first.  Conjugation of cyclic RGD to G4 PAMAM did not significantly alter 
polymer toxicity at the ligand labeling densities or polymer concentrations tested.  
PAMAM-RGD cytotoxicity at the higher 53.5 µg/mL concentration resulted in slightly 
 151 
lower mean cell viability for each polymer, but viability did not decrease below 83% for 
any polymer at the higher concentration.  Further, viability data for both concentrations 
were not significantly different in all four cell lines (Figure 4.3).   
 
Figure 4.3.  Cytotoxicity of PAMAM-RGD polymers was determined as the normalized 
metabolic activity of each cell line in the presence of two concentrations of polymer. Polymer 
concentration of 10.7 µg/mL corresponds to typical in vitro transfection conditions at N/P 
ratio of 10.  Metabolic activity was normalized to cells grown in the absence of polymer. The 
standard deviation is shown for each data point (N = 6, error bars represent standard 
deviation). 
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Polyplex Gel Retardation 
Electrostatic interactions are the basis for PAMAM-DNA polyplex formation.  We have 
shown in Chapters 2 and 3 that unmodified PAMAM formed the charge neutral polyplex 
at a relatively low N/P ratio ≤ 2.  We seek to determine whether conjugation of RGD 
ligands to PAMAM affects this measure of polymer-DNA binding.  To determine the 
amount of polymer required to form charge-neutral polyplexes, polymer and plasmid 
were mixed at N/P ratios 1, 1.5, and 2 and subjected to gel electrophoresis (Figure 4.4).  
Neutral and positively-charged polyplexes remain in the loading wells, while negatively-
charged polyplexes and free DNA migrate through the gel.  The polyplex composition at 
which DNA and polyplexes do not enter the gel is defined as the charge-neutral N/P ratio, 
and is a measure of polymer-DNA interaction.   
 
Figure 4.4. DNA gel retardation with PAMAM RGD polymers.  The N/P ratio used to 
form each polyplex is given above the corresponding lane.   
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Conjugation of RGD ligand to the dendrimer did not significantly alter N/P ratio of the 
charge neutral polyplex.  Charge neutrality was achieved between N/P 1.5 and 2 for all 
polymers.  We note that charge neutrality in the PAMAM-Fol and PAMAM-Tf polymers 
with highest ligand valency also occurred between N/P 1 and 2. 
 
Polyplex Sizing 
Sizes of integrin-receptor targeted PAMAM polyplexes in saline solution were 
determined by dynamic light scattering.  Particle sizes were approximately 250 nm for 
unmodified PAMAM, and between 160-220 nm for integrin-receptor targeted polyplexes 
at the same N/P ratio (Table 4.2).   
Table 4.2. Polyplex sizing immediately after formation in 20 mM PIPES, 150 mM NaCl.  
Polyplexes were prepared at N/P ratio 10 and subjected to dynamic light scattering on a 
particle size analyzer (N = 4). 
 Effective diameter  (nm) 
PAMAM 240.6 ± 16.2 
PAMAM-RGD 0.31 217.5 ± 10.7 
PAMAM-RGD 0.77 210.4 ± 4.4 
PAMAM-RGD 1.13 176.5 ± 13.3 
PAMAM-RGD 1.81 160 ± 27.3 
PAMAM-RGD 2.25 172.2 ± 10.7 
PAMAM-RGD 4.6 196.9 ± 7.2 
 
Smaller polyplexes were formed with targeted PAMAM compared with unmodified 
PAMAM.  In general, PAMAM and PAMAM-RGD polyplexes ranged in size from 160 
nm to 240 nm.  These sizes are comparable to those formed with PAMAM-Fol and –Tf 
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shown in Chapter 3.  Polyplexes formed in saline solution are ~50% larger than those 
formed in deionized water, but four to five times smaller than those formed in growth 
media containing 10% fetal bovine serum (data not shown).  Solvent-dependent changes 
in polyplex size are most likely the result of polyplex aggregation. 
 
Gene Delivery Activity of PAMAM-RGD 
Gene delivery was tested across a range of N/P ratios in four cells lines: HeLa and SiHa 
cells that expressed the αVβ3 integrin receptor, and CHO and HepG2 cells that did not.  
Receptor-mediated endocytosis and gene delivery were demonstrated in the two αVβ3 
expressing cell lines. 
 
PAMAM-RGD gene delivery activity in the four cell lines varied with αVβ3 receptor 
expression.  Transfection in αVβ3 deficient CHO cells decreased with increasing amounts 
of targeting ligand (Figure 4.5A).   
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Figure 4.5. In vitro transfection of cells not expressing αVβ3 integrin receptor:(A) CHO, and 
(B) HepG2 cells with PAMAM-RGD at indicated N/P ratios.  Luciferase activity in the cell 
lysates is reported as relative light units (RLU) divided by the mass of total protein in the 
lysate, and normalized to transfection efficiency of unmodified PAMAM N/P 10.  
 
In vitro transfection of (C) CHO and (D) HepG2 cels with PAMAM-RGD polyplexes (N/P 
ratio of 10) in the presence of free ligand.  Luciferase activity in the cell lysates is reported 
as relative light units (RLU) divided by the mass of total protein in the lysate, and 
normalized to transfection efficiency in the absence of free ligand.   
 
(N = 5; error bars represent standard deviation.) 
 
 
 
C
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This may be due to intracellular sorting of the foreign ligand and its polyplex cargo to 
pathways leading to less efficient gene delivery.  Human HepG2 cells, which in our 
cultures also did not express the αvβ3 receptor, demonstrated relatively small changes 
during transfection with PAMAM-RGD polymers compared to unmodified PAMAM 
(Figure 4.5B).  Gene delivery did increase up to three-fold with PAMAM-RGD 0.31 and 
0.77 in HepG2 cells.  We believe this phenomenon is explained by enhanced intracellular 
trafficking of the PAMAM-RGD polyplex that is not related to αvβ3 receptor-mediated 
endocytosis.  As discussed in previous chapters, slight changes in polyplex composition 
may significantly affect polyplex navigation within the cell.  This is not surprising 
considering that there exists a milieu of intracellular sorting vesicles with varying pH, 
trafficking destinations, and even durations of cargo retention, among other variables.  
 
HeLa and SiHa cells expressing the αVβ3 receptor demonstrated up to twelve-fold 
increases in gene delivery when transfected with PAMAM-RGD polyplexes (Figure 
4.6A, B).  Enhanced gene delivery in these two cell lines was demonstrated to be receptor 
specific in transfection experiments with free ligand.  The presence of 100 µM RGDfC in 
growth medium was sufficient to reduce gene delivery of the most targeted PAMAM-
RGD polymers by 35-55% in these two cell lines (Figure 4.6C, D).  CHO and HepG2 
cells, which did not express αVβ3 protein, exhibited non-significant changes to PAMAM-
RGD gene delivery under these conditions (Figure 4.5C, D). 
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Figure 4.6. In vitro transfection of cells expressing αVβ3 integrin receptor: (A) HeLa and (B) 
SiHa cells with PAMAM-RGD at indicated N/P ratios.  Luciferase activity in the cell lysates is 
reported as relative light units (RLU) divided by the mass of total protein in the lysate, and 
normalized to transfection efficiency of unmodified PAMAM N/P 10.  
 
 In vitro transfection of (C) HeLa and (D) SiHa cells with PAMAM-RGD polyplexes (N/P ratio 
of 10) in the presence of free ligand.  Luciferase activity in the cell lysates is reported as 
relative light units (RLU) divided by the mass of total protein in the lysate, and normalized to 
transfection efficiency in the absence of free ligand.   
 
(N = 5; error bars represent standard deviation.) 
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As previously observed, optimal gene delivery with PAMAM-RGD 0.31-1.13 in HeLa 
cells (N/P ratio 10) was 3-6 fold higher than that of untargeted PAMAM.  In comparison, 
gene delivery with the same polymers in αVβ3 deficient HepG2 cells was only 3-fold 
better than baseline.  This is further evidence of receptor-mediated gene delivery 
resulting in in efficient transfection.   
 
Our ELISA results showed that SiHa cells expressed twice the amount of αVβ3 receptor 
per cell protein mass as compared with HeLa cells.  In HeLa cells, gene delivery 
increased 3-6 fold at N/P ratio 10 with optimal PAMAM-RGD 0.31 and 0.77 polymers 
compared to unmodified PAMAM.  In comparison, PAMAM-RGD gene delivery 
increased 10-12 fold in SiHa cells at the same N/P ratio with all but one PAMAM-RGD 
polymer.  PAMAM-RGD 4.6 - the polymer with the highest ligand valency and targeting 
to the integrin receptor - effected relatively poor gene delivery in all cells lines and N/P 
ratios tested.  We have shown that polyplexes formed with this polymer are compact and 
achieve charge neutrality at a low N/P ratio.  Net uptake of PAMAM-RGD 4.6 
polyplexes was also not significantly different from that of other PAMAM-RGD or 
unmodified PAMAM polyplexes (vide infra).  It is not unreasonable to assume low 
transfection therefore resulted from poor endocytic trafficking, perhaps due to a pathway 
similar to that traversed by multivalent PAMAM-Tf with ligand valency in excess of the 
optimal PAMAM to transferrin ratio (Chapter 3). 
  
We are also able to comment upon the relationship between gene delivery effectiveness 
and N/P ratio in each cell line.  This parameter reveals polymer dependency on the 
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proton-sponge effect for transfection, and sheds light on the role of acidification in 
PAMAM and PAMAM-RGD endocytic pathways that may be cell-line dependent.  
Comparing gene delivery amongst N/P ratios in HeLa cells revealed progressive 
increases in transfection from N/P ratio 2-20.  At N/P ratio 20, gene delivery eventually 
reached 10- to 12-fold over unmodified PAMAM.  Even PAMAM-RGD 1.81 and 2.25 
polymers, which did not demonstrate enhanced gene delivery in HeLa cells at N/P ratio 
of 10, exhibited 6-fold increases over unmodified PAMAM at N/P 20.  PAMAM-RGD 
1.81 and 2.25 polymers are thus only efficient at higher N/P ratios in this cell line.  We 
hypothesize that at higher N/P ratios the presence of additional buffering polymer 
facilitates successful endosomal escape via a proton sponge mechanism.  Such an 
observation points to some degree of PAMAM-RGD polyplex internalization via an 
acidified pathway in HeLa cells.  Consistent with current literature, this pathway is a 
source of gene delivery inefficiency and can be overcome by the addition of buffering 
capacity to polyplexes at higher N/P ratios.  Whether this proportion of PAMAM-RGD 
polyplexes is taken up via αVβ3 receptors, or non-specific electrostatic interactions at the 
cell surface, will be addressed after assessing PAMAM-RGD gene delivery in the SiHa 
cell line.   
 
Compared with HeLa cells, SiHa cells expressed over twice the amount of αVβ3 integrin 
receptor.  Since the RGD ligand leads to efficient gene delivery in cells expressing the 
αvβ3 receptor, we logically expected to, and did in fact, observe higher overall gene 
delivery in SiHa cells than HeLa cells with PAMAM-RGD polymers.  Interestingly, we 
observed a much weaker relationship between N/P ratio and PAMAM-RGD gene 
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delivery in SiHa cells.  In SiHa cells gene delivery of the receptor-targeted polymers does 
not change significantly between N/P 10 and N/P 20.  Uniformly high PAMAM-RGD 
gene delivery levels in 10-fold excess of unmodified PAMAM are evident at N/P 10, 13.5, 
and 20.  Only marginal increases in transfection effectiveness are noted when additional 
polymer is used within this window of N/P ratios.  A striking comparison between the 
HeLa and SiHa cell lines occurs in N/P ratio 10 polyplexes: polyplexes formed with 
PAMAM-RGD 1.81 and 2.25 did not outperform untargeted PAMAM in HeLa cells, but 
did in SiHa cells by over ten-fold.  The minimal dependence of PAMAM-RGD gene 
delivery on N/P ratio in SiHa cells suggests that these polyplexes undergo comparatively 
low acidification as they are trafficked within SiHa cells.  The potentially beneficial 
buffering effect of the PAMAM proton-sponge at higher N/P ratios is thus minimized in 
this pathway - one that leads to a high degree of gene delivery activity.  Thus, we believe 
that αVβ3 receptor-specific internalization of PAMAM-RGD polyplexes in SiHa cells 
does not result in trafficking to low pH endolysosomes. 
 
After observing PAMAM-RGD gene delivery in SiHa cells we are able to offer a more 
concrete explanation regarding the strongly positive relationship between gene delivery 
and N/P ratio in HeLa cells.  This phenomenon was especially pronounced in polyplexes 
formed with PAMAM-RGD 1.81 and 2.25.  We hypothesize that in HeLa cells a portion 
of these polyplexes at N/P 10 were internalized via a receptor-independent pathway 
leading to acidified vesicles.  At N/P 10 these polyplexes are unable to escape the 
endosome effectively, thus sharing a similar fate and efficiency as unmodified PAMAM 
polyplexes.  It is only at higher N/P ratios 13.5 and 20 that PAMAM-RGD 1.81 and 2.25 
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polyplexes escaped the endosome via the proton-sponge effect.  Subsequently, the 
presence of RGD ligand on the released polyplex resulted in enhanced gene delivery.  We 
note that PAMAM-RGD 1.81 and 2.25 polyplexes entering the cell via αVβ3 receptor-
specific mechanisms do not traverse this acidified trafficking pathway.  Gene delivery 
studies in the presence of endocytic inhibitors and endosomal buffering agents in 
subsequent sections will be used to confirm the validity of these inferences. 
 
Uptake of PAMAM-RGD with Free RGD Ligand 
We conducted flow cytometry studies of αvβ3 receptor targeted PAMAM using YOYO-1 
tagged pGL3 in the presence or absence of free ligand.  We sought to determine whether 
the evidence of receptor-specific endocytosis seen with gene delivery (previous section) 
would also be reflected in polyplex uptake.  Results show that net uptake of polyplexes 
remained unaffected by the presence of RGD ligand in the transfection medium in all 
four cell lines tested (Figure 4.7).   
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This is the expected result for CHO and HepG2 cell lines that did not express αvβ3 
integrin.  It is also unsurprising in HeLa and SiHa cells considering that previous flow 
cytometry results have shown uptake to be a poor indicator of gene delivery.  In 
competitive binding uptake studies using free ligand in HeLa and SiHa cells, it is likely 
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Figure 4.7. Normalized uptake of YOYO-1 labeled pGL3 and PAMAM-RGD polyplexes (N/P 
ratio of 10) in the presence of free RGD in (A) CHO, (B) HepG2, (C) HeLa and (D) SiHa 
cells.  Fluorescence values were normalized to the median fluorescence of cells transfected in 
the absence of free RGD.  (N=5; error bars represent standard deviation.) 
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that free ligand is indeed competing with PAMAM-RGD for the αvβ3 receptor.  However, 
it is also likely that PAMAM-RGD polyplexes displaced from the receptors by free 
ligand are still being internalized at the cell surface by non-receptor-specific mechanisms 
of endocytosis.   
 
This explanation is consistent with data from the previous section showing decreases in 
gene delivery with PAMAM-RGD polyplexes in the presence of free ligand (Figure 
4.6C, D).  We have established that gene delivery via the αVβ3 receptor leads to 
successful transfection.  Under competitive binding conditions, fewer PAMAM-RGD 
polyplexes are internalized via receptor specific means, and more are internalized via a 
low efficiency, acidified pathway.  While net uptake remains unchanged, gene delivery 
activity declines. 
 
We did not show absolute uptake values of PAMAM and PAMAM-RGD polyplexes in 
this study as they did not vary significantly from each other.  This is similar to polyplex 
uptake results with PAMAM-Fol in Chapter 3.  We note that PAMAM-Fol and 
PAMAM-RGD polymers were synthesized across a similar range of ligand densities 
(between 0.3-7 ligands per polymer).  Both Fol and RGD ligands were ~500 Da 
molecular weight.
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Transfection Following Selective Endocytic Inhibition with Small Molecule Drugs  
We performed gene delivery experiments with αvβ3 receptor-targeted PAMAM in the 
presence of endocytic inhibitors and buffering agents.  The goal was to determine the 
mechanism of uptake and trafficking responsible for successful gene delivery with 
PAMAM-RGD.  We studied the effects of buffering agents on gene delivery because 
endosomal acidification plays an important role in identifying the type of pathway 
involved in polyplex trafficking.   
 
Inhibition of caveolae with genistein or cholesterol depletion decreased PAMAM-RGD 
gene delivery by at least 50% in HepG2, HeLa, and SiHa cells (Figures 4.8, 4.9).  
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Figure 4.8.  Normalized in vitro transfection efficiency of PAMAM-RGD  polyplexes 
(N/P ratio of 10) in (A) CHO and (B) HepG2 cells that do not express αVβ3 integrin 
receptor.  Transfection was performed in the presence of caveolae inhibitors 
genistein, 50 µg/mL; methyl-β-cyclodextrin, 10 mg/mL; clathrin inhibitors 
chlorpromazine, 5 µg/mL; and amantadine, 1 mM.  Luciferase activity in the cell 
lysates is reported as relative light units (RLU) divided by the mass of total protein in 
the lysate.  Luciferase activity of drug-treated cells was normalized to cells grown in 
the absence of any inhibitors.  (N = 5; error bars represent standard deviation.) 
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Figure 4.9. Normalized in vitro transfection efficiency of PAMAM-RGD polyplexes (N/P 
ratio of 10) in (A) HeLa and (B) SiHa cells that express αVβ3 integrin receptor.  
Transfection was performed in the presence of caveolae inhibitors genistein, 50µg/mL; 
methyl-β-cyclodextrin, 10 mg/mL; clathrin inhibitors chlorpromazine, 5 µg/mL; and 
amantadine, 1 mM.  Luciferase activity in the cell lysates is reported as relative light 
units (RLU) divided by the mass of total protein in the lysate.  Luciferase activity of drug-
treated cells was normalized to cells grown in the absence of any inhibitors.  (N = 5; 
error bars represent standard deviation.) 
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While we detected minimal levels of caveolin-1 in our HepG2 cell lines (Table 4.1), it is 
possible that similar, cholesterol-dependent lipid raft mechanisms of endocytosis still 
exist in this cell line.  Previous work has shown that the expression of caveolin-1 in 
caveolae-deficient cells is sufficient to induce caveolae [61, 62].  Thus, pre-existing 
membrane cholesterol and lipid rafts that play a role in caveolae may also be present in 
these cells, contributing to cholesterol-dependent endocytosis that occurs in the absence 
of caveolin-1.  Transfection results from these three cell lines are similar to that from 
previous chapters studying PAMAM-Fol and –Tf gene delivery in HeLa cells, where 
both targeted and untargeted PAMAM gene delivery showed a dependence on caveolar 
trafficking.  It would appear that, at least in human cell lines, caveolae and caveolar 
trafficking is the common denominator required for successful PAMAM gene delivery 
regardless of receptor targeted. 
 
Interestingly, in the CHO cell line inhibition of caveolae with genistein actually increased 
gene delivery.  We note that CHO cells express the highest amount of caveolin-1 protein 
per cell protein weight of the four cell lines.  Perhaps inhibiting this mechanism of uptake 
resulted in polyplexes being internalized via an efficient, non-caveolar pathway.  
Cholesterol depletion with mCD in CHO cells did not appreciably affect PAMAM or 
PAMAM-RGD gene delivery.  Inhibition of clathrin with chlorpromazine and 
amantadine decreased PAMAM and PAMAM-RGD gene delivery in CHO cells.  This is 
the first time we have observed decreased PAMAM gene delivery in cells transfected in 
the presence of anti-clathrin drugs.  Compared with gene delivery results in human cell 
lines tested in this and previous chapters, the interplay of caveolae and clathrin in CHO 
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gene delivery is anomalous.  It is possible that different mechanisms of endocytosis and 
gene delivery predominate in CHO cells.   
 
Integrin-receptor targeted gene delivery amongst HepG2, HeLa, and SiHa cells is a 
particular interesting comparison.  All three are human epithelial cancer cells lines, with 
different levels of integrin receptor, clathrin, and caveolin expression.  All three exhibit a 
dependence on caveolin for successful targeted and untargeted PAMAM gene delivery.  
However, gene delivery behavior responses differ during clathrin inhibition and 
endosomal buffering. 
 
Gene delivery activity of PAMAM and PAMAM-RGD in HepG2, HeLa, and SiHa cells 
increased or stayed constant in the presence of clathrin pathway inhibiting drugs.  We 
have already proposed an explanation for how transfection may increase when one form 
of endocytosis is inhibited: polyplexes on the cell surface may be internalized via other 
mechanisms leading to higher efficiency.  Additionally, compensatory mechanisms of 
uptake may even be upregulated, leading to higher uptake via a more efficient gene 
delivery pathway.   
 
The phenomenon of increased gene delivery upon clathrin inhibition is most pronounced 
in HeLa cells.  Five- to seven-fold increases in gene delivery were uniformly observed 
with all polymers over gene delivery under drug-free conditions.  Of the three human cell 
lines studied, Western Blots showed HeLa cells to have the highest concentration of 
clathrin per cell protein mass.  This suggests that clathrin-coated pit endocytosis accounts 
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for a larger proportion of endocytosis in HeLa cells than in the other cell lines tested.  
Vesicles formed from these clathrin-coated pits are typically sorted to low pH 
endolysosomes, which have been shown to be a source of inefficiency for polymer-based 
gene delivery [48, 49, 63-71].  If this predominant mechanism of clathrin endocytosis is 
effectively inhibited in HeLa cells, it stands to reason that the proportion of polyplexes 
normally entering via coated pits is now available to be endocytosed via other clathrin-
independent means.  The 7-fold increases in gene delivery upon clathrin pathway 
inhibition supports the theory that the alternative clathrin-independent pathways lead to 
efficient transfection.    
 
PAMAM and PAMAM-RGD gene delivery in SiHa cells also increased upon clathrin 
pathway inhibition, but only by 50-150%.  We attributed this to the lower expression of 
clathrin in SiHa cells compared with that of HeLa cells.  Inhibition of this pathway thus 
had a smaller effect on gene delivery in this cell line.   
 
SiHa cells overexpress the αvβ3 receptor.  We have demonstrated that αVβ3 receptor 
specific gene delivery yielded an order of magnitude transfection increase (Figure 4.6B) 
in this cell line.  During clathrin inhition, gene delivery with unmodified and minimally 
targeted PAMAM-RGD gene delivery increased the most (150%).  Highly targeted 
PAMAM-RGD exhibited minimal changes to gene delivery under the same drug 
conditions (0-50%).  Given that PAMAM-RGD polymers more targeted to the αvβ3 
receptor were less affected by clathrin depletion in SiHa cells, we believe that a sizeable 
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proportion of the αvβ3 receptor is associated with clathrin-independent regions of the cell 
membrane.   
 
Subsequent gene delivery experiments were conducted with endosomal buffering agents 
to determine the role of acidification in PAMAM-RGD gene delivery (Figures 4.10-11).  
Bafilomycin-A1 is a proton pump inhibitor that acts upon endolysosomal compartments, 
among several targets.  The effect of chloroquine in plasmid gene delivery is two-fold: 1) 
intercalating DNA and preventing nuclease degradation of the plasmid, and 2) 
accumulating in endolysosomes and buffering pH decreases.  We have discussed the 
actions of these two drugs in Chapter 3. 
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Figure 4.10. Normalized in vitro transfection efficiency of PAMAM-RGD  polyplexes 
(N/P ratio of 10) in (A) CHO and (B) HepG2 cells that do not express αVβ3 integrin 
receptor.  Transfection was performed in the presence of endosomal buffering agents 
bafilomycin A1, 10 nM and chloroquine, 20 µM.  Luciferase activity in the cell lysates 
is reported as relative light units (RLU) divided by the mass of total protein in the 
lysate.  Luciferase activity of drug-treated cells was normalized to cells grown in the 
absence of any inhibitors.  (N = 5; error bars represent standard deviation.) 
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Figure 4.11. Normalized in vitro transfection efficiency of PAMAM-RGD  polyplexes 
(N/P ratio of 10) in (A) HeLa  and (B) SiHa cells that express αVβ3 integrin receptor.  
Transfection was performed in the presence of endosomal buffering agents bafilomycin 
A1, 10 nM, and chloroquine, 20 µM.  Luciferase activity in the cell lysates is reported as 
relative light units (RLU) divided by the mass of total protein in the lysate.  Luciferase 
activity of drug-treated cells was normalized to cells grown in the absence of any 
inhibitors.  (N = 5; error bars represent standard deviation.) 
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The proton-pump inhibiting action of bafilomycin significantly decreased gene delivery 
of all targeted and untargeted PAMAM polyplexes in CHO and HepG2 cells by 
approximately 70%.  This suggests that targeted and untargeted polyplexes depend upon 
acidification for endosomal escape and successful gene delivery in these two cell lines 
that do not express the αvβ3 receptor.  Interestingly, chloroquine had minimal effect in 
enhancing endosomal escape of these polymers.  PAMAM-RGD 4.6, which exhibited 
poor gene delivery under drug free conditions, notably exhibited a five-fold increase in 
gene delivery in HepG2 cells.  We surmise that PAMAM-RGD 4.6 polyplexes are 
normally sorted to low pH endolysosomes for degradation because its high polymer 
ligand valency is beyond optimal ranges for receptor-mediated gene delivery.  The 
beneficial effects of chloroquine buffering in this environment would therefore be evident 
in PAMAM-RGD 4.6 gene delivery. 
 
Unmodified PAMAM gene delivery in HeLa cells decreased by nearly 50% in the 
presence of bafilomycin.  This result is similar to previous work with PAMAM and 
bafilomycin shown in Chapter 3.  PAMAM polyplexes entering HeLa cells via a clathrin 
route are dependent upon endosomal acidification for the proton-sponge mechanism to 
take effect.  Acidification, followed by osmotic swelling and rupture of the endosome, are 
prerequisites for PAMAM polyplex escape into the cytosol and subsequent gene delivery.  
Our results show that this is not the mechanism by which the majority of PAMAM-RGD 
polyplexes that have been successfully internalized via receptor-specific means effect 
gene delivery.  Compared with CHO and HepG2 cells, the inhibitory effect of 
bafilomycin was minimal amongst the αvβ3 targeted polymers in both HeLa and SiHa 
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cells.  Chloroquine similarly had little effect on gene delivery in these two αvβ3 
expressing cell lines.  Changes that did occur as a result of endosomal buffering were 
more evident in HeLa and than SiHa cell lines.  It would thus appear that αvβ3 targeted 
polymers in both these cell lines avoid the endolysosome, or at least intracellular 
locations where bafilomycin and chloroquine would directly effect pH.   
 
We note that in SiHa cells PAMAM-RGD 4.6 demonstrated decreased gene delivery in 
the presence of both buffering agents.  PAMAM-RGD 4.6 effected poor gene delivery in 
all cell lines compared under drug-free conditions.  We proposed that this was due to 
non-optimal ligand valency resulting in altered intracellular trafficking.  As a result, the 
behavior of this polymer in the presence of both endosomal inhibitors and buffering 
agents is dissimilar from that of other, more optimally targeted, PAMAM-RGD vehicles. 
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Uptake Following Selective Endocytic Inhibition with Small Molecule Drugs 
Flow cytometry experiments with YOYO-1 tagged PAMAM-RGD polyplexes were 
conducted to determine the effect of endocytic uptake inhibitors on net internalization of 
polyplexes (Figure 4.12).   
 
Figure 4.12. Normalized median fluorescence of (A) CHO, (B) HepG2, (C) HeLa and (D) 
SiHa cells transfected with YOYO-1 labeled pGL3 and PAMAM-RGD (N/P ratio of 10) in the 
presence of caveolae (genistein, 50 μg/ml; methyl-β-cyclodextrin, 10 mg/ml) and clathrin 
(chlorpromazine, 5 μg/ml; amantadine, 1 mM) inhibitors.  Fluorescence values were 
normalized to the median fluorescence of cells transfected in the absence of drugs. (N = 5; 
error bars represent standard deviation.) 
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We addressed how cellular regulation of endocytosis affects design and interpretation of 
uptake data in Chapters 2 and 3.  Our previous studies have highlighted the limitations of 
using flow cytometry and endocytic inhibitors to downregulate internalization 
mechanisms in understanding the gene delivery process.  Namely, net polyplex uptake is 
an indicator of the combined effect of multiple endocytic routes, and inhibition of one 
pathway has a multiplicity of effects on other pathways. 
 
Gene delivery results showed that clathrin pathway inhibition increased PAMAM-RGD 
gene delivery in αVβ3-expressing SiHa and HeLa cell lines (Figure 4.9).  We thus 
inferred that a proportion of targeted polyplexes are internalized via an inefficient 
clathrin-mediated route in these cells.  When the clathrin endocytic mechanism is 
inhibited, these polyplexes may still be internalized via more efficient, non-clathrin 
means.  Flow cytometry data indicating approximately zero change in net polyplex 
uptake during SiHa and HeLa transfection with anti-clathrin drugs supports this theory.  
We also note that uptake of PAMAM-RGD 0.31-1.13 appears to be cholesterol 
dependent in HeLa cells, but not SiHa cells, despite the relative abundance of caveolae in 
both cervical epithelial cell lines.   
 
PAMAM-RGD uptake profiles during clathrin or caveolae pathway inhibition are very 
similar between CHO and HepG2 cell lines (Figure 4.12A, B).  Despite this, their gene 
delivery profiles are very different.  In both cell lines, perturbation of membrane 
cholesterol with mCD, but not caveolae interruption with genistein, decreased uptake.  
It would appear that endocytosis of PAMAM-RGD polyplexes in these cells that do not 
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express the αVβ3 receptor is consistently dependent on membrane cholesterol.  
Interestingly, of these two cell lines gene delivery decreased only in the human HepG2 
cell line with mCD.  Although genistein did not affect PAMAM-RGD internalization, it 
dramatically decreased gene delivery in HepG2 cells, while increasing it over seven-fold 
in CHO cells.  These results indicate that net uptake and gene delivery can be very 
separate, and cell-specific, processes.  Further evidence for this is seen in HepG2 and 
CHO cell polyplex uptake in response to clathrin pathway inhibition.  Chlorpromazine-
mediated interruption of clathrin pit formation greatly decreased PAMAM-RGD polyplex 
uptake for both cell types, while amantadine only had a minimal effect on internalization.  
Yet both chlorpromazine and amantadine are purported to sequester clathrin 
intracellularly by similar mechanisms [72-75].  In attempting to correlate this data with 
gene delivery, we observe that transfection with amantadine decreased in CHO cells, but 
increased in HepG2 cells.   
 
Our previous studies of uptake and gene delivery were conducted only in the HeLa cell 
line.  In Chapters 2 and 3 we concluded that uptake does not accurately reflect gene 
delivery.  This assessment also applied to our present flow cytometry experiments, which 
we expanded to four cell lines studying internalization of PAMAM-RGD polyplexes.  
That uptake and gene delivery processes are cell specific is not disputed.  We have 
attempted to correlate these cell-specific differences to variations in expression of the 
αVβ3 integrin receptor, clathrin heavy chain, and caveolin-1 proteins.  While gene 
delivery data suggest that trafficking of PAMAM-RGD polyplexes internalized via αVβ3 
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occurs successfully through non-acidified, non-clathrin routes, our uptake data neither 
conclusively supports nor refutes this hypothesis. 
 
Cytotoxicity 
We transfected CHO, HepG2 and SiHa cells in the presence of endocytosis inhibitors as 
well as endosomal buffering agents to understand the interplay of gene delivery 
trafficking mechanisms and pathways in these cells.  The drugs significantly affected 
gene delivery activity.  However, cell viability was not significantly affected (>70%) as 
measured with Cell Titer Blue and XTT toxicity assays (Figures 4.13-15).   These results 
are similar to previously reported effective drug concentrations [48, 49, 76].   
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Figure 4.13.  Cytotoxicity of caveolae (genistein, methyl-β-cyclodextrin) and clathrin 
(chlorpromazine, amantadine) inhibitor drugs, and endosomal buffering drugs 
(bafilomycin, chloroquine) was determined as the normalized metabolic activity of CHO 
cell line in the presence of  varying amounts of the drugs. Metabolic activity was 
normalized to cells grown in the absence of drugs. Red arrows indicate the highest 
concentration at which drugs were administered during cell experiments. The standard 
deviation is shown for each data point (N = 6, error bars represent standard deviation). 
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Figure 4.14.  Cytotoxicity of caveolae (genistein, methyl-β-cyclodextrin) and clathrin 
(chlorpromazine, amantadine) inhibitor drugs, and endosomal buffering drugs 
(bafilomycin, chloroquine) was determined as the normalized metabolic activity of HepG2 
cell line in the presence of  varying amounts of the drugs. Metabolic activity was 
normalized to cells grown in the absence of drugs. Red arrows indicate the highest 
concentration at which drugs were administered during cell experiments. The standard 
deviation is shown for each data point (N = 6, error bars represent standard deviation). 
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Figure 4.15.  Cytotoxicity of caveolae (genistein, methyl-β-cyclodextrin) and clathrin 
(chlorpromazine, amantadine) inhibitor drugs, and endosomal buffering drugs 
(bafilomycin, chloroquine) was determined as the normalized metabolic activity of SiHa 
cell line in the presence of  varying amounts of the drugs. Metabolic activity was 
normalized to cells grown in the absence of drugs. Red arrows indicate the highest 
concentration at which drugs were administered during cell experiments. The standard 
deviation is shown for each data point (N = 6, error bars represent standard deviation). 
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Conclusions 
We successfully synthesized PAMAM-RGD polymers that formed compact, charge 
neutral polyplexes with pGL3 at low N/P ratios.  These polyplexes were internalized via 
both cell surface αVβ3 receptors and non-specific means in cells expressing the integrin 
protein.  They were also taken up in HepG2 and CHO cell lines via non-receptor specific 
mechanisms. 
 
The results presented in this chapter demonstrate that PAMAM polyplexes targeted to 
αVβ3 integrin receptors lead to successful gene delivery.  Significant acidification is not 
associated with the trafficking of polyplexes internalized with the αVβ3 receptor.  To date, 
the kinetics of integrin receptor uptake, intracellular trafficking, and final cargo 
destination, have not been determined.  In the context of gene delivery, we believe the 
αVβ3 receptor is endocytosed largely via clathrin-independent means.   
 
This is consistent with transfection results in HeLa cells from the previous chapters.  
Interruption of caveolar trafficking leads to unsuccessful gene delivery with both targeted 
and untargeted PAMAM.  In all the human cell lines tested in our studies, we found that 
polyplexes trafficked through non-clathrin mechanisms undergo minimal acidification.  
Polyplexes regularly trafficked through highly acidified compartments are dependent on 
the proton-sponge mechanism for endosomal escape, which is impeded by the presence 
of buffering agent bafilomycin A1.  In fact, the most efficient of the targeted polyplexes 
(PAMAM-Fol, -Tf, and -RGD) were least likely to experience acidification, and thus 
least affected by cellular treatment with bafilomycin. 
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PAMAM-RGD gene delivery in CHO cells was conducted as a control not only for αVβ3 
protein, but also for the trafficking dissimilarities inherent to differences between human 
and murine cell lines.  In contrast to PEI, PAMAM, and all targeted PAMAM gene 
delivery experiments in human cells, inhibition of caveolae in CHO cells led to several-
fold increased gene delivery activity with polymers.  We conclude that endocytosis and 
intracellular trafficking is very cell-specific.  Changing patterns of endocytosis observed 
during perturbation of cell surface clathrin and caveolin with inhibitors cannot be 
generalized across cell lines.  Similarly, correlations between uptake and gene delivery in 
one cell line cannot be applied to another. 
 
Synthesis of PAMAM-RGD polymers across a range of polymer-ligand ratios allowed us 
to identify the ligand valency leading to optimal receptor targeting and gene delivery.  As 
with our previous PAMAM-Fol and PAMAM-Tf studies (Chapter 3), increased targeting 
does not necessarily lead to enhanced gene delivery.  While we concluded that trafficking 
via the αVβ3 receptor pathway generally leads to successful gene delivery through non-
acidified compartments, PAMAM-RGD 4.6 gene delivery was reduced compared with 
unmodified PAMAM controls.  We have demonstrated that PAMAM-Tf 0.75 gene 
delivery is inefficient potentially due to receptor oligomerization when binding to 
multivalent transferrin protein.  It is possible that PAMAM-RGD 4.6 polyplexes also 
induce lumenal retention or recycling signals that lower gene delivery efficiency.  This 
proposed recycling pathway corresponds to polyplex routing to highly acidified 
compartments - potentially the endolysosome. 
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Finally, we demonstrated that the presence of the RGD ligand in cells without the αVβ3 
receptor can result in intracellular sorting of polyplexes to pathways leading to effective 
gene delivery.  Receptor-mediated endocytosis is not a necessary prerequisite for 
trafficking along pathways similar to that traversed by the receptor.  HepG2 cells did not 
express αVβ3 integrin and exhibited small, but significantly increased, gene delivery 
activity with certain optimal PAMAM-RGD polymers compared with unmodified 
PAMAM.  This trafficking pathway was also minimally acidified and largely 
independent of clathrin coated pits. 
 
We have thus shown that conjugation of RGD to PAMAM results in enhanced trafficking 
in human cells leading to gene delivery.  Receptor-specific mechanisms of uptake via cell 
surface αVβ3 can yield an order of magnitude increase in transfection.  This mechanism, 
and its subsequent trafficking, shares important characteristics with other targeted and 
untargeted polyplexes that effect high gene delivery levels: they are minimally acidified, 
and highly dependent on functional caveolae for transfection. 
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Experimental 
Cells and Plasmids 
The HeLa human cervical carcinoma cell line used in this study was a gift from Dr. 
Sandra McMasters (University of Illinois, Urbana, IL).  CHO, HepG2, and SiHa cell lines 
were purchased from the American Type Culture Collection.  The cells were cultured 
according to their ATCC protocols at 37 °C and 5% CO2 in Dulbecco's modiﬁed Eagle's 
medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.  
 
Luciferase plasmid pGL3 (Elim Biopharmaceuticals, San Diego, CA) carried the reporter 
gene used to assess gene delivery vehicle efficiency.  The plasmid encodes the firefly 
luciferase protein, driven by the SV40 promoter and enhancer domains.  Plasmid 
production, purification, and quality control were conducted by Elim Biopharmaceuticals. 
 
Generation of RGD Conjugated PAMAM 
PAMAM-RGD conjugates were prepared as in Waite et al. [50].  Generation 4 PAMAM 
dendrimer was dissolved in of phosphate buffered saline (PBS) with 1 mM EDTA 
(reaction buffer) at a polymer concentration of 10 mg/mL.  To generate SPDP-activated 
PAMAM, sulfo-LC-SPDP cross-linker (Pierce, Rockford, IL) was added to the polymer 
solution at various molar ratios and stirred at 25 °C for 3 hours.  The activated PAMAM 
product was purified from reactants by gel filtration chromatography (PD-10, GE 
Healthcare, Uppsala, Sweden) and quantified by ninhydrin assay.  The number of SPDP 
groups attached to PAMAM was determined using UV absorbance to quantify pyridine-
2-thione (P2T) released when SPDP-activated PAMAM is cleaved by disulfide reducing 
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agent DTT.  P2T has a UV absorbance at 343 nm.  Briefly, we measured 343 nm 
absorbance of a 1 mL sample of 1 mg/mL activated PAMAM to indicate background 
signal.  To the same sample, 5 μL of DTT (Pierce, Rockford, IL) (15 mg/mL) was added, 
and the absorbance at 343 nm was recorded after a 15 min incubation at 25 °C.  The 
increase in UV absorbance observed after the addition of DTT corresponded to the 
addition of LC-SPDP groups to dendrimers. The average molar ratio of SPDP:PAMAM 
was calculated according to the manufacturer’s protocol (Pierce, Rockford, IL). 
 
RGDfC peptide (Peptides International, Louisville, KY) was subsequently added in 
excess of SPDP to activated PAMAM, and stirred overnight at 25 °C to generate the final 
PAMAM-RGD conjugated.  PAMAM-RGD was purified from unreacted PAMAM by 
gel filtration chromatography (PD-10, GE Healthcare, Uppsala, Sweden).  PAMAM 
concentration was quantified using ninhydrin assay, and RGD ligand valency was 
confirmed using absorbance at 343 as described above.  Successful replacement of P2T 
groups by RGD peptide resulted in 343 nm absorbance values not significantly different 
from background when DTT is added to the PAMAM-RGD sample. 
 
Physical Characterization of Ligand-Polymer/DNA Polyplexes.   
Stoichiometry of polymer-DNA complexation. The stoichiometry of polymer-DNA 
complex formation can be observed as a reduction of mobility of the polyplexed DNA in 
agarose gel electrophoresis.  The lowest polymer/DNA ratio at which polyplexes remain 
immobile was identified as the charge-neutral polyplex.   
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Polyplex Sizing with Dynamic Light Scattering.  Polyplexes were prepared using 3.0 µg 
DNA diluted in 20 mM PIPES, 150 mM NaCl, and polymer then added to bring the total 
polyplex volume to 250 µL for a given polymer-DNA (N/P) ratio.  Following 20 min 
incubation at room temperature, polyplexes were transferred to a transparent cuvette and 
diluted with deionized water to a final volume of 1.8 mL.  Each sample was subjected to 
size measurement on a Brookhaven Instruments Corporation 90 Plus Particle Size 
Analyzer (Holtsville, NY) immediately after dilution, and again after 2 h, 4 h, 6 h, and 24 
h at room temperature.   
 
Enzyme-Linked Immunosorbent Assay (ELISA) of αVβ3 Protein 
Duoset IC Human Total Integrin αVβ3 ELISA kit (RND Systems, Minneapolis, MN) was 
used to quantify cellular αVβ3 protein content.  Cells were solubilized at 1 x 107 cells/mL 
in lysis buffer and centrifuged at 2000 x g for 5 minutes.  The supernate was kept on ice 
until further use.  RND Systems protocol was followed for ELISA plate preparation.  
PBS buffer was prepared at pH 7.2 and used for all wash steps.  Briefly, 100 µL of 8 
µg/mL capture antibody was added to each well in a 96 well plate and incubated at 25 °C 
overnight before washing with PBS buffer.  Each well was filled with RND Systems 
Block Buffer and incubated at 25 °C for 1 hour, followed by aspiration and another wash.   
 
100 µL of sample was added to each well and incubated for 2 hours at 25 °C, prior to 
aspiration and PBS buffer wash.  100 µL RND Systems Detection Antibody was then 
added to each well at 200 ng/mL, incubated for 2 hours at 25 °C, aspirated and washed.  
100 µL streptavidin horseradish peroxidase was added to each well and incubated for 20 
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minutes at 25 °C in the dark, aspirated and washed.  This was repeated with RND 
Systems Substrate Solution, without aspiration and wash.  Finally, 50 µL RND Systems 
Stop Solution was added to each well.  Absorbance at 450 nm was read immediately, 
with baseline correction at 540 nm.   
 
Western Blot of Clathrin Heavy Chain and Caveolin-1 
Western blots of whole cell lysates were performed to verify the presence of clathrin 
heavy chain (CLTC) and caveolin-1 (CAV-1) using the colorimetric WesternBreeze 
Chromogenic Western Blot Immunodetection Kit (Invitrogen, CA).  Anti-CLTC and 
CAV-1 antibodies were sourced from Santa Cruz Biotechnologies (CA).  Caveolin-1 
and clathrin heavy chain primary antibodies were used at a 1:500 dilution. 
 
Polyplexes/Transfections 
HeLa cells were seeded at 70,000 cells/well in 24 well plates 24 h prior to transfection. 
Polymer/pGL3 complexes were prepared at room temperature by mixing 1 mg/mL 
polymer in 150 mM NaCl, 20 mM PIPES, pH 7.2, with 1 mg/mL pGL3 in endotoxin free 
water, to achieve the desired N/P ratio.  Polyplexes were then incubated at room 
temperature for 10 min.  Prior to transfection, the growth media was replaced with serum-
free media and 50 µl of polyplexes was added to each well.  In experiments using 
endocytic inhibiting drugs, drugs were added to serum free media 30 minutes before 
transfection.  Drugs were used in transfection medium at the following concentrations: 
genistein, 50 µg/mL; methyl-β-cyclo-dextrin, 10 mg/mL; chlorpromazine, 5 µg/mL; 
amantadine, 1 mM; bafilomycin, 10 nM; and chloroquine, 20µM.  The transfection 
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medium was removed and replaced with serum supplemented media 4 h post-transfection.  
Luciferase expression was quantified 48 h post-transfection using the Promega luciferase 
assay system (Promega, Madison, WI).  Luciferase activity was measured in relative light 
units (RLU) using a Lumat LB 9507 luminometer (Berthold, GmbH, Germany), and was 
subsequently normalized by total cell protein using the Pierce BCA protein assay kit 
(Pierce, Rockford, IL) to yield RLU/mg protein.  All results were normalized to gene 
delivery activity of G4 PAMAM or PEI at N/P 10 in the absence of drugs.   
 
Flow Cytometry/Uptake Studies  
The protocol followed was identical as for transfections. Additionally, the pGL3 plasmid 
was tagged with intercalating dye YOYO-1 was added, at 1 molecule of dye / 100 base 
pairs.  Two hours post-transfection, the cells were rinsed twice with 0.001% SDS in PBS 
and PBS, respectively, to remove surface-bound complexes.  Next, 100 µl of 0.25% 
trypsin in PBS was added to each well.  The cells and trypsin were allowed to incubate 
for 5 minutes before 50 µl of fetal bovine serum was added to each well.  The cells were 
then collected and stored on ice.  FACS analyses were performed on a Coulter EPICS 
XL-MCL flow cytometer (Beckman-Coulter, Fullerton, CA).  Uptake was measured 
using the following formula 
 
 
0,10
,
blanksample
yxblanksample
FF
FF


 
where  blank is autofluorescence of untreated cells 
 x = N:P ratio of sample 
 y = drug concentration 
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Normalization was done by comparing the corrected fluorescence to N:P = 10 and in the 
absence of drugs 
 
Cytotoxicity 
Cytotoxicity of endocytosis inhibiting drugs was characterized in CHO, HepG2 and SiHa 
cells using the CellTiter-Blue cell viability assay (Promega, Madison, WI).  Cytotoxicity 
of these drugs was previously determined in HeLa cells in Chapter 2.  The assay 
measures the ability of live cells to metabolize resazurin into its fluorescent, reduced end-
product, resorufin.  Briefly, cells were seeded in 96-well microplates at 2 × 104 cells/well 
and grown in medium containing 10% bovine serum and 1% penicillin-streptomycin at 
37°C, 5% CO2.  Growth medium was replaced with serum free DMEM 24 h after seeding.  
Endocytosis inhibiting drugs were added at the following concentrations: genistein, 0-
62.5 µg/mL; methyl-β-cyclo dextrin, 0-12.5 mg/mL; chlorpromazine, 0-6.25 µg/mL; 
amantadine, 0-12.5 mM.  DMEM along with inhibiting drugs were aspirated after four 
hours incubation and replaced with growth medium.  Plate was incubated for a further 20 
h.  Subsequently, 20μl of the CellTiter-Blue reagent was added to each well and 
incubated for an additional 4 h.  Absorbance was read at 570 nm. The background 
absorbance of cells killed with ethanol was subtracted from the viable cell absorbance. 
Each experiment was repeated six times at each drug concentration.  
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CHAPTER 5 
Comments and Future Work 
 
The research presented in this dissertation seeks to better understand non-viral gene 
delivery mechanisms.  As outlined in Chapter 1, vehicle transport from the plasma 
membrane to the nucleus represents a major barrier to polymeric gene delivery.  An 
incomplete understanding of the trafficking pathways involved in gene delivery limits 
rational design of gene delivery vehicles.  We have chosen to study PEI and PAMAM – 
prototypical proton-sponge polymers – in the hope that the principles elucidated from 
their study can be generally applied across cell lines and vehicle types.   
 
Although many classes of endocytosis have been identified, we elected to focus on 
clathrin- and caveolae-based uptake because they are the most extensively characterized 
pathways.  Further, their vesicles vary across the spectra of trafficking destinations and 
intraluminal conditions.  They also play important roles in the uptake of many receptors 
that serve as disease biomarkers.  Our results in Chapter 2 point to the existence of a 
complex intracellular sorting milieu involving both clathrin and caveolae.  While the 
extent of their intra-pathway sorting capacity is poorly characterized, we have shown that 
these two pathways unlikely function independently of one another.  This is not 
surprising considering that both forms of endocytosis can lead to successful gene delivery 
with non-viral vectors, suggesting that they share, at the very least, some elements 
common to effective trafficking.  Our uptake data from this and subsequent chapters 
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consistently indicate that polyplex uptake mechanism, not quantity, is ultimately 
reflective of delivery success. 
 
Chapter 3 established baseline endocytic and trafficking behavior for ligands associated 
with clathrin-coated pits and caveolae in the plasma membrane.  In support of our 
findings from the previous chapter, we demonstrated that effective gene delivery could 
occur via polyplexes endocytosed in clathrin-coated pits or caveolae.  Yet, most 
noteworthy is that inhibition of caveolar transport drastically inhibited successful gene 
delivery with all targeted polymers.  We found that common to the best performing folic 
acid- and transferrin-receptor targeted polymers was minimal trafficking through 
acidified compartments.  This is consistent with lysosomal avoidance being a key step in 
non-viral gene delivery, regardless of initial uptake mechanism.  Previous research has 
shown that both poor and effective gene delivery may occur with polyplexes internalized 
by clathrin-coated pits; our successful gene delivery experiments via the clathrin 
mechanism indicated that the fates of endosomal contents can vary widely, and are 
affected by the receptor type or attached polyplex cargo. 
 
Results presented in Chapter 4 demonstrated successful gene delivery via the αVβ3 
integrin receptor.  In comparing delivery across cell lines with increasing levels of αVβ3 
receptor expression, we observed a lessening dependence on the proton-sponge effect for 
transfection.  This is consistent with gene delivery effectiveness correlating to receptor 
specificity and lysosomal avoidance.  While the precise mechanism of αVβ3 receptor 
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trafficking is unknown, our results show that it bears the greater resemblance to that of 
the folic acid receptor located in caveolae. 
 
It is well-established that caveosomes undergo minimal acidification, and that clathrin 
vesicles are associated with lower pH and the endolysosome.  This body of work presents 
evidence that both uptake mechanisms may share downstream sorting pathways in 
common, especially in the context lysosomal avoidance required for successful gene 
therapy.  The design of a single vehicle capable of navigating multiple cellular barriers 
must take this into account.  Many parameters regulate the route an endocytosed particle 
takes through a cell, not the least of which is the ligand used to target cells within 
heterogenous tissue in vivo. 
 
